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Abstract 
Neural tube defects (NTDs) are a common class of human birth defects with a 
complex, multifactorial etiology.  Although many contributing factors have been 
identified, an estimated 60% of human population risk remains unexplained.  A portion 
of that risk is likely attributable to gene-gene and gene-environment interactions which 
have yet to be fully elucidated.   In one project, we used whole-exome sequencing to 
identify candidate genetic factors in a multiplex anencephaly family, revealing an 
aggregation of rare and common variants in planar cell polarity genes among the 
affecteds.  In the second project, we profiled the methylomes of a pair of monozygotic 
twins discordant for anencephaly and identified several differentially methylated sites 
which could contribute to NTD risk, particularly the mir-886 locus.  Finally, we 
performed whole-exome and whole-methylome sequencing of mouse strains with 
differential susceptibility to fumonisin-induced NTDs, in combination with a human 
SNP association study.  We identified epigenetic changes and variant associations which 
implicate Wnt and Hippo signaling genes as modifiers of the metabolic impacts of 
fumonisin exposure. These findings underscore the complexity of NTD pathogenesis 
and highlight the need to elucidate gene-gene and gene-environment interactions 
contributing to NTD etiology. 
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Chapter 1: Neural tube defects 
1.1 Morphogenesis of the neural tube 
The neural tube (NT) is the precursor to the vertebrate central nervous system 
(reviewed in Greene and Copp, 2009).  Most of the NT forms by primary neurulation, 
which for our purposes will be considered synonymous with ‘neurulation’ (Figure 1A).  
Briefly, neurulation begins with induction of the neural plate, a thickened region of 
dorsal ectoderm, above the notochord.  The cells of the neural plate subsequently 
undergo convergent extension (Figure 1B), converging upon and intercalating along the 
plate midline, causing the neural plate to both lengthen and narrow.  The lateral edges 
of the neural plate, termed the neural folds, elevate and converge above the midline 
through a combination of cell shape changes (cf. apical constriction at hinge points), cell 
rearrangements and division (Ezin et al., 2009), and extrinsic forces from the adjacent 
epithelium (Alvarez and Schoenwolf, 1992).  The neural folds then meet and fuse to 
close the neural tube.  Fusion is initiated at multiple discrete sites and proceeds outward 
to ‘zipper’ the neural tube closed, with the cranial region closing around day 26 and 
caudal around day 28 in human development. 
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Figure 1.  Overviews of A) primary neurulation and B) convergent extension. 
Patterning of the neural tube is coordinated primarily by interactions between 
canonical Wnt, Shh, and BMP (TGF-β superfamily) signaling pathways.  BMPs act as 
dorsal patterning signals, originating with the roofplate and defining dorsal cell identity 
(Chesnutt et al., 2004), while SHH signaling originates with the notochord and defines 
ventral cell identity (Roelink et al., 1995).  BMPs are also required to maintain the 
roofplate after its formation, and pattern the expression of Wnt signaling components 
along the dorsal-ventral axis (Chesnutt et al., 2004).  Members of the Wnt pathway also 
promote cell proliferation and dorsal identity, partly through regulation of BMP 
signaling (Bonner et al., 2008), and antagonize Shh signaling to constrain ventral cell 
patterning (Yu et al., 2008).  Generally, deficits in dorsal identity (Chesnutt et al., 2004) 
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and/or aberrant expansion of ventral patterning (Ybot-Gonzalez et al., 2002) result in a 
failure of neural tube closure.  Other processes intimately linked to neural tube 
specification and closure include primary cilium morphogenesis and intraflagellar 
transport, required for Shh signaling (Huangfu et al., 2003), and noncanonical Wnt 
signaling (planar cell polarity, or PCP), which orchestrates convergent extension 
(Wallingford and Harland, 2002).  Wnt signaling, canonical and non-canonical alike, is 
described in further detail below (Section 1.3.2). 
1.2 Neural tube defects 
1.2.1 NTD phenotypes 
Neural tube defects (NTDs) arise from defective closure of part or all of the 
neural tube, and are among the most common of human birth defects.  Here we focus on 
failures of primary neurulation, which are classified into the phenotypes spina 
bifida (SB), the failure of closure in caudal regions of the neural tube; anencephaly (AN), 
failure of closure in the cranial neural tube; and craniorachischisis (CR), failure along the 
length of the neural tube.   
Anencephaly is characterized by the absence of the forebrain and cranial vault; 
infants with AN may survive to term, and for hours to days after birth, but the 
phenotype is ultimately lethal.  In lieu of the forebrain is the area cerebrovasculosa, a mass 
of fibrovascular tissue containing some neural elements (Elwood et al., 1992).  The 
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midbrain and cerebellum may or may not develop, while the brain stem is generally 
present but incomplete.  Evidence suggests that in some cases, the forebrain may 
initially develop but degrade over time (Cafici and Sepulveda, 2003), referred to as the 
acrania-anencephaly sequence.  In model organisms, the most prevalent cranial NTD is 
exencephaly, in which cerebral tissue overgrows through the open cranial vault; the 
exposed tissue frequently degrades if gestation is continued, producing an anencephalic 
phenotype (Matsumoto et al., 2002). 
Spina bifida encompasses lesions arising from defective closure of the caudal 
neural tube.  These can be subdivided into a number of phenotypes based upon the 
tissue types present in the lesion, including meninges, neural tissue, and/or fatty tissue.  
Spina bifida can also be categorized by lesion level (e.g. thoracic, lumbar).  This 
phenotype is frequently accompanied by tethering, the abnormal attachment of the 
spinal cord to adjacent tissues, and hydrocephalus, the obstruction of cerebrospinal fluid 
drainage from the brain (Greene and Copp, 2009).  Unlike other NTD phenotypes, SB 
cases are generally viable.  Spina bifida co-occurs infrequently with AN; only some 20% 
of mouse models exhibit both phenotypes (Harris and Juriloff, 2007). 
1.2.2 Prevalence of NTDs and therapeutic interventions 
Between 1996 and 2000, the overall global prevalence of AN was 2.1 per 10,000 
births, and 3.4 per 10,000 births for SB (Lie, 2006).  However, prevalences varied widely 
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between regions, ranging from 0.4 per 10,000 AN cases in Spain to 13.5 per 10,000 in 
Mexico, and 2.3 per 10,000 SB cases in the U.S. to 14.4 per 10,000 in Mexico.  Some 
variability in prevalences can be explained by confounding factors in ascertainment, 
such as the inclusion or exclusion of terminations and the use of a population-based or 
hospital-based study design; however, genetic background and regional environmental 
factors also vary by region and/or ethnicity.  For example, consistently high prevalences 
have been recorded for regions including China, India, Mexico, and the Middle-East 
(Lie, 2006).  One of the highest incidences of NTDs recorded is ascribed to a four-county 
region in Shanxi Province, with 1.4 affecteds per 100 births (Li et al., 2006).  All told, 
NTDs collectively represent a considerable public health burden around the globe. 
The U.S. fully implemented mandatory fortification with folic acid in 1998.  
Subsequently, the prevalences of AN and SB have declined by upwards of 20% and 34% 
respectively (Canfield et al., 2005).  Folic acid supplementation, whether by maternal 
vitamins or through fortification, is the only known preventative strategy for NTDs.  
Furthermore, while SB may be corrected with postnatal or even in utero surgery, 
prevention is the only treatment for more severe NTD phenotypes.  Recent studies 
indicate that the U.S. population is now largely folate-replete, and no longer exhibit 
association between NTD risk and maternal folate intake (Mosley et al., 2009).  This 
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suggests that folate supplementation has largely succeeded in preventing folate-
sensitive NTDs, and new strategies will be needed to address the remainder of cases.   
Using data from the National Birth Defects Prevention Study (1997-2007), 
Agopian et al. examined the contributions of risk factors in the fortified U.S. population 
for both AN and SB (Agopian et al., 2013).  They found that overall, some 60% of 
population NTD risk remains unexplained.  Major known risk factors included obesity 
(2-10%), Hispanic ethnicity (8-15%), low dietary folate intake (4-10%), and female infant 
sex (8%, AN only).  Their data also shows that while family history of NTDs increases an 
individual’s risk considerably (odds ratio 7-9), as a population risk factor, family history 
explains only some 2% of risk. However, under the generally accepted oligogenic model 
of NTD etiology, a portion of that unexplained risk may be ascribable to genetic factors 
which are not necessarily detrimental except in the right (or wrong) combinations. 
1.3 Genetic processes contributing to NTD etiology 
NTD etiology is known to have a strong genetic component.  Although most 
human cases are sporadic, with only one affected in a family, siblings of a case are on 
average 32 times more likely to be affected than the general population (Elwood et al., 
1992) .  However, association studies in humans have had limited success in identifying 
and replicating genetic associations of candidate genes (reviewed in Au et al., 2010; 
Juriloff and Harris, 2012).  Difficulties of studying NTDs in humans include the low 
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recurrence rates and lethality of most phenotypes; small sample sizes and poor statistical 
power for many studies; and heterogeneity of phenotypes and populations.  Most 
established NTD candidate genes have been identified through animal models, 
particularly the generation of knockout strains in mice.   
Using mouse models, over 240 genes have been implicated in NTD risk, a list 
which is not yet considered exhaustive (Harris and Juriloff, 2007, 2010).  That said, many 
candidate genes fall into a central set of pathways and processes, including but not 
limited to Hedgehog signaling, primary cilium morphogenesis and function, chromatin 
structure, regulation of actin cytoskeleton dynamics, and noncanonical Wnt or planar 
cell polarity (PCP) signaling.  As the most directly relevant to our research and findings, 
we focus here on folate metabolism, Wnt signaling, and chromatin modifications. 
1.3.1 Folate metabolism 
The single human SNP most robustly associated with NTDs is rs1801133, in 5,10-
methylenetetrahydrofolate reductase (MTHFR).  This SNP causes an Ala 222 > Val 
substitution which produces a thermolabile form of the protein, and has been estimated 
to explain up to 19% of NTDs, including a majority of folate-sensitive NTDs (Ou et al., 
1996).  Other variants in MTHFR and in other genes relating to folate metabolism, such 
as cystathionine β-synthase, thymidylate synthase, and methionine synthase reductase, 
have also evidenced modest contributions to NTD risk (Shaw et al., 2009a).  
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Figure 2.  Overview of folate metabolism. 
Folate derivatives are required for nucleotide synthesis (purines and thymine), 
protein synthesis (cysteine and methionine), formate metabolism, and methylation 
reactions; defects in all of these processes have been implicated in NTD etiology either 
directly or indirectly (reviewed in Beaudin and Stover, 2009). Deficiency in thymidylate 
synthesis, for example, is characteristic of the splotch mouse strain, a model system with 
completely penetrant NTDs in homozygotes (Fleming and Copp, 1998).  In an example 
of more indirect connections, nucleotide and protein synthesis are essential for cell 
proliferation, and defects of proliferation can impair closure (Copp et al., 1988).  Finally, 
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one-carbon metabolism and methylation reactions have become a topic of particular 
interest in NTD research, discussed in more detail below (Section 1.4.1). 
1.3.2 Wnt signaling 
As described above, Wnt signaling plays important roles in the morphogenesis of 
the neural tube.  In the canonical branch, secreted Wnt ligands bind to Frizzled (Fzd) 
family receptors and Low density lipoprotein receptor-related protein (LRP) co-
receptors  (reviewed in Nusse, 2012).  This leads to formation of a complex involving 
Disheveled (Dvl) family members, Axin, and Glycogen synthase kinase 3 (GSK3).  The 
complex inhibits phosphorylation of β-catenin by GSK3, allowing β-catenin to 
translocate to the nucleus and convert transcription factors of the TCF/LEF family from 
repressors to activators of Wnt target genes.  The different activities of canonical Wnt 
signaling in NT development can largely be segregated by ligand.  Mitogenic effects are 
driven by ligands WNT1 and WNT3A (Megason and McMahon, 2002), while other 
family members are specific to dorsal (WNT3) or ventral (WNT5A, WNT7A/7B) regions, 
and some (e.g. WNT4) are expressed more broadly (Parr et al., 1993). 
Non-canonical Wnt signaling determines planar cell polarity: the organization of 
cells within a plane of tissue, orthogonal to the apical-basal axis (reviewed in Gray et al., 
2011).  Core PCP genes are conserved from invertebrates through mammals, and include 
Frizzled (FZD3 and FZD6), cadherin, EGF LAG seven-pass G-type receptors (CELSR1-3), 
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Van Gogh-like (VANGL1-2), Dishevelled (DVL1-3), Prickle (PRICKLE1-4), and ankyrin 
repeat domain 6 (ANKRD6).  Mouse knockouts of many of these genes have defects in 
convergent extension which result in NTDs.  PCP signaling is also essential for 
ciliogenesis and Shh signaling (Park et al., 2006). 
Briefly, in vertebrate PCP signaling (reviewed in Gray et al., 2011), Wnt ligands 
(WNT5/11) bind to FZD receptors which complex with CELSR proteins to activate 
DVLs.  CELSR proteins may also complex with VANGL family members, which 
antagonize the activating complex, likely required for propagating polarity among 
adjacent cells.  Activated DVL complexes with disheveled associated activator of 
morphogenesis 1 (DAAM1), Rac, and Rho, leading to activation of downstream effectors 
which regulate actin cytoskeleton dynamics and drive changes in cell shape.  In model 
systems where defective PCP signaling impairs convergent extension, the neural tube 
remains too wide for the folds to meet and fuse (Wallingford and Harland, 2002).  
Several studies on humans have implicated rare variants or putative mutations of PCP 
genes in human NTD etiology, but have not investigated the contributions of more 
common alleles (reviewed in Juriloff and Harris, 2012). 
1.4 Environmental factors contributing to NTD risk 
A number of non-genetic factors have been implicated in NTD pathogenesis.  
Folate deficiency is among the best-known, but other dietary deficiencies which may 
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contribute to risk include methionine (Shoob et al., 2001), vitamin B12 (Ray et al., 2007), 
zinc (Velie et al., 1999), selenium (Cengiz et al., 2004), and inositol (Cockroft et al., 1992).  
In addition to deficiencies, a number of early-pregnancy exposures have been implicated 
in NTD risk, including alcohol (Liu et al., 2009; Wang and Bieberich, 2010), cotinine 
(Shaw et al., 2009b), a variety of metals (Huang et al., 2011; Jin et al., 2013), medications 
such as valproic acid or trichostatin A (Menegola et al., 2005),  and the mycotoxin 
fumonisin (Gelineau-van Waes et al., 2005; Missmer et al., 2006).  Aspects of maternal 
health and metabolism, such as obesity and diabetes (Hendricks et al., 2001; Moore et al., 
2000) or first-trimester illness and fever (Shaw et al., 1998) also associate with greater 
risk of NTDs.  As with genetic contributions to NTD pathogenesis, the array of 
implicated environmental factors is large and complex, with many opportunities for 
interactions; here we focus on two elements, one-carbon metabolism and exposure to the 
mycotoxin fumonisin. 
1.4.1 One-carbon metabolism, methylation reactions, and chromatin 
structure 
The folate derivative 5-methyltetrahydrofolate is necessary for the regeneration 
of methionine from homocysteine (Figure 2).  Methionine, in the form of S-
adenosylmethionine, is the carbon donor for most methylation reactions in the cell 
(Kozbial and Mushegian, 2005).  After methyl transfer, S-adenosylhomocysteine is 
converted to homocysteine, allowing the cycle to continue.  Thus, folate metabolism is 
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intimately connected to methylation reactions, and the aberrant methylation of DNA, 
histones, and other molecules may contribute to NTD pathogenesis. 
Support for this hypothesis comes from a number of directions.  In addition to 
folate deficiency, methionine (Shoob et al., 2001) and vitamin B12 (Ray et al., 2007) 
deficiencies have been associated with increased NTD risk, B12 being another essential 
cofactor for methionine synthase.  The HDAC inhibitors valproic acid and trichostatin A 
(Menegola et al., 2005) are both NTD-inducing teratogens.  Knockout mice lacking the 
DNA methyltransferases Dnmt1 (Li et al., 1992) or Dnmt3b (Okano et al., 1999) exhibit 
NTDs, and family member Dnmt3a has been shown to regulate neural and neural crest 
cell fate (Hu et al., 2012).  Additionally, hypomethylation of brain tissue (Chen et al., 
2010) and generally aberrant DNA methylation profiles (Chang et al., 2011) have been 
observed in human NTD cases, with a suggestion of greater hypomethylation 
correlating to more severe NTD phenotypes.  Related to this, epigenetic factors have 
been suggested as an explanation for the female excess observed in AN (Gelineau-van 
Waes and Finnell, 2001); methylation of the second X chromosome causes a greater 
demand for methyl groups during development in females than in males.  However, it 
remains to be determined whether aberrant methylation or other epigenetic 
modifications actively contribute to NTD pathogenesis in humans, and if so, what 
proportion of risk they may explain. 
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1.4.2 Fumonisin exposure and sphingolipid metabolism 
1.4.2.1 The mycotoxin fumonisin and NTD risk 
Fumonisins are a class of mycotoxins produced by Fusarium species, particularly 
F. verticillioides (reviewed in Stockmann-Juvala and Savolainen, 2008).  Although 15 
different fumonisins have been identified, fumonisin B1 (FB1) is the most prevalent by 
far, and for the purposes of this paper will be considered “fumonisin”.  A study of 
global occurrence detected FB1 in 50-60% of food and feed materials worldwide, with 
the greatest prevalence in South American samples (Schatzmayr and Streit, 2013). 
Animal studies have associated FB1 with equine encephalomalacia, hepatic cancer, 
pulmonary oedema, liver damage, and kidney damage (reviewed in Stockmann-Juvala 
and Savolainen, 2008).  Finally, and of most relevance to this research, some mouse 
strains exhibit NTDs when treated with FB1 (Gelineau-van Waes et al., 2005).  However, 
at present little is known about fumonisin toxicity in humans, or its contribution to 
human NTD risk. 
Evidence connecting fumonisin to human NTD pathogenesis is largely 
circumstantial.  Regions in China, South Africa, and Latin America with high maize 
consumption also exhibit high NTD prevalences (reviewed in Marasas et al., 2004).  
Additionally, and maize tortilla consumption has been significantly associated with 
NTD risk (Missmer et al., 2006).  These data, although circumstantial, support a closer 
investigation of FB1 as a potential risk factor for human NTDs. 
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1.4.2.2 Inhibition of sphingolipid biosynthesis by FB1 
Fumonisin is known to competitively inhibit ceramide synthases due to 
structural similarity with their substrates (Figure 3).  These enzymes (CERS1-CERS6 in 
humans) attach fatty acid groups to sphingoid bases to produce ceramides, which are 
key intermediates in sphingolipid metabolism (reviewed in Pewzner-Jung et al., 2006).  
Inhibition of ceramide synthase results in an excess of simple sphingolipids sphingosine 
(So) and especially sphinganine (Sa), and concomitant depletion of ceramide (Cer) and 
its derivatives (sphingomyelin, glycosphingolipids).   
sphinganine
sphingosine
ceramide
fumonisin B1
 
Figure 3.  Structures of key sphingolipids and fumonisin B1. 
Sphingolipids are important membrane components, but ceramide, Sa, and So 
are also bioactive lipids with key regulatory functions (reviewed in Mencarelli and 
Martinez–Martinez, 2013).  Sphingosine promotes growth arrest, while its 
phosphorylated form (So1P) promotes proliferation.  Conversely, Cer promotes 
apoptosis, and ceramide-1-phosphate (Cer1P) promotes cell survival; implicitly, 
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maintaining the balance between sphingolipid species is critical to cell function and 
survival.  Additionally, ceramide has been implicated in primary cilium morphogenesis 
(Wang et al., 2009), which is necessary for Hedgehog signaling.  Sphingolipids are also 
involved in the regulation of differentiation and cell migration, and can act as 
intracellular messengers, binding to specific G-protein-coupled receptors (S1PR1-S1PR5) 
on the surfaces of cells (reviewed in Maceyka et al., 2012). These receptors have been 
implicated in a number of processes and diseases, from immune responses to diabetes.  
Finally, So1P has been shown to inhibit HDAC1 and HDAC2, suggesting a role for 
simple sphingolipids in regulating epigenetic modifications. 
1.5 A model of differential susceptibilities: LM/Bc and SWV mice 
Human NTDs are not generally detected until much later in development, after 
the germ layers have differentiated and exposed tissues have had opportunity to 
degrade.  This lag between defect formation and discovery has negative repercussions 
for retrospective studies, when exposures which contributed most to pathogenesis 
occurred weeks or months before ascertainment.  It impairs epigenetic and gene 
expression experiments, as the most proximal tissues – the neural plate and surrounding 
elements – cannot be readily obtained; and particularly for open NTDs, such as AN, 
even differentiated neural tissues may be absent or degraded about the defect site.  
Finally, the genetic heterogeneity of human NTDs, described briefly above, can be a 
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confounding factor in its own right.  Model organisms thus occupy a critical niche in 
NTD research, providing tractable systems in which these issues can be minimized. 
In collaboration with the Gelineau-van Waes lab at Creighton University, we 
used the LM/Bc and SWV mouse strains as a model of the interactions between genetic 
and environmental risk factors.  These strains are relatively closely related, with LM/Bc 
mice having been outcrossed to SWV mice in 1968; inbreeding was resumed with F1 
individuals who were 1/8 SWV and 7/8 LM/Bc, and the strain has since been maintained 
as a closed, inbred colony (Harris et al., 1984).  Yet despite this shared heritage, these 
strains have strikingly different responses to environmental factors.  SWV mice are 
highly susceptible to NTDs induced by anticonvulsant drugs (Finnell et al., 1988) and 
elevated maternal body temperature (Finnell et al., 1986), while LM/Bc mice are highly 
susceptible to NTDs induced by the mycotoxin fumonisin (Gelineau-van Waes et al., 
2005).  Each strain is also relatively resistant to factors the other is sensitive to.  These 
mirror-image responses constitute an excellent model system for studying genetic 
modifiers of NTD risk. 
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Chapter 2: The contributions of genetic factors to NTD 
etiology 
Association studies in humans have had limited success in identifying and 
replicating genetic association of candidate genes and variants  (reviewed in Au et al., 
2010; Juriloff and Harris, 2012).  This difficulty arises in part from the genetic 
heterogeneity of NTDs, exemplified by the over 240 candidate genes identified from 
mouse models (Harris and Juriloff, 2007, 2010).  However, though the accepted model 
for NTD etiology is multifactorial, involving both genetic and environmental risk 
factors, interactions between risk factors remain relatively understudied in the field.  
Here we have identified candidate gene-gene interactions which may contribute to NTD 
pathogenesis using whole-exome sequencing in a multiplex human family and in a 
mouse model of differential NTD susceptibilities.  Our data underscore the importance 
of genetic background to the etiology of highly penetrant as well as sporadic NTDs.   
2.1 Oligogenic etiology in humans 
We performed whole-exome sequencing on all members of a multiplex NTD 
family, including both parents, three anencephalic children, and one unaffected child.  
We hypothesized that the multiple occurrence of anencephaly would be due to a single 
highly penetrant genetic lesion homozygous in affected individuals and heterozygous in 
unaffected family members.  However, we found no variant that fit this model.  Instead, 
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we identified a collection of heterozygous rare and common variants within PCP 
signaling genes which were enriched in the affected offspring.  This is to our knowledge 
the first study to take a cumulative, pathway-level approach for identifying potential 
interacting variants which is inclusive of both rare and common human alleles. 
2.1.1 Methods 
2.1.1.1 Sample collection and clinical information 
The Hereditary Basis of Neural Tube Defects study at Duke University Medical 
Center has been enrolling participants since 1996 and the cohort consists of over 5,000 
individuals with all types of NTDs (Section 1.2.1) and their family members.  The study 
includes both singleton and multiplex families.  Ascertainment of participants occurs 
across the United States from a variety of sources including referral by genetic 
counselors, physicians, support groups and self-referral in response to advertisements 
by the study team. We selected a single AN multiplex NTD family for whole-exome 
sequencing because of the availability of DNA from both parents, an unaffected sibling, 
and three separate AN pregnancies.   
The family was of European ethnicity, with no prior history of NTDs, and 
affecteds included male and female individuals.  Fetal tissue and/or cord blood samples 
were collected by the participant’s physician at the time of termination or delivery for all 
four offspring.  Blood samples were obtained from both parents.  A detailed family 
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history was obtained, and medical records including ultrasound reports and images 
were collected to confirm the diagnosis; relevant clinical information is given in Table 1.  
This study was conducted under the oversight of Duke University Medical Center 
Institutional Review Board and informed consent was obtained from all participants. 
Table 1. Clinical information for included pregnancies in the multiplex family. 
 A1 A2 A3 U 
Phenotype AN AN AN normal 
Sample type tissue tissue 
FFPE 
tissue 
cord blood 
Folate suppl. no no yes yes 
Maternal multivitamin no no yes yes 
Other supplementation --- --- inositol 
B complex, C, D, E, 
calcium, coenzyme Q10, 
alpha-lipoic acid 
Maternal BMI normal normal normal normal 
Other medication Zoloft Zoloft Zoloft Zoloft, antibiotics 
 
2.1.1.2 Exome library preparation and sequencing 
DNA was extracted from fetal tissue (affecteds A1 and A2), cord blood 
(unaffected), and peripheral blood (parents) by the Duke University DNA Bank and 
Tissue Repository on a Gentra Automated DNA Extractor using Puregene chemistry.  
Only formalin-fixed, paraffin embedded (FFPE) slides were available for affected A3; 
DNA was extracted from the FFPE slides by Genewiz according to their in-house 
protocol, and also by QIAamp DNA FFPE Tissue kit (Qiagen) for validation 
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experiments.  Protein-coding regions were enriched for all samples using the TruSeq 
exome capture kit (Illumina, Inc., San Diego, CA), which targets 201,121 exons in 20,794 
genes. Paired-end 100 nt reads were generated using an Illumina HiSeq instrument.  
Sample libraries for the father, affected A1, and affected A2 were generated at the Duke 
Center for Human Genetics Molecular Genomics Core facility and sequenced by the 
David H. Murdock Research Institute.  Both library preparation and sequencing were 
performed by GENEWIZ, Inc. for all other samples. 
2.1.1.3 Alignment and variant calling 
Raw reads were aligned to the NCBI human reference genome build 37.1 using 
Burrows-Wheeler Aligner (Li and Durbin, 2009).  Unmapped and duplicate reads were 
removed using samtools (Li et al., 2009) and PICARD (Wysoker et al., 2009) respectively. 
Local realignment around indels and base quality score recalibration were performed 
using Genome Analysis Toolkit (GATK) version 2.5 (DePristo et al., 2011).  Single 
nucleotide variants were called simultaneously across all samples using the Unified 
Genotyper in GATK, constrained to ‘target intervals’ within 400 nt of any capture probe.  
The default sample contamination parameter (5%) was used for all samples except 
affected A2, which preliminary analysis determined was contaminated with maternal 
DNA, most likely at the time of termination.  The contamination threshold for that 
sample was set at 10% after evaluation of maternal allele overrepresentation at 
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parentally homozygous sites; this corrected most erroneous genotype calls.  Variants 
were phased for each child with the PhaseByTransmission tool in GATK.  Finally, low-
quality variants were filtered out according to the Broad Institute’s recommendations for 
small sample sets as given in GATK documentation (Van der Auwera et al., 2013).   
Variants were annotated against human RefSeq genes using ANNOVAR (Wang et al., 
2010) with a neargene threshold of 2 kb. 
2.1.1.4 Variant segregation analysis 
Sites where affecteds A1 and A2 both called homozygous for the minor allele, 
but not either parent or the unaffected, were considered to potentially segregate with 
phenotype.  Due to expectation of a large detrimental effect, variants were further 
constrained to non-synonymous common SNVs and all SNVs with a minor allele 
frequency of less than 5%.  Data was reviewed manually at these sites to exclude 
variants with low coverage or nearby indels affecting genotype calls. 
2.1.1.5 Haplotype transmission analysis 
Sites heterozygous in only one parent were used to construct haplotype blocks 
across each covered gene.  Haplotypes for children A2, A3, and U were scored on their 
differences from to the corresponding haplotype of child A1, with 0 being an exact 
match.  No penalty was assigned for missing data.  We initially filtered on genes 
showing dual segregation of parental haplotypes with affection status, allowing up to 
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20% mismatch to accommodate possible calling errors.  Subsequently, we filtered on 
genes where only one parental haplotype segregated with affection status, and followed 
up on variants transmitted by the opposite parent in those and other interacting genes. 
2.1.1.6 Validation of novel variants 
Primers for the validation of novel variants in PAX6 and TEAD1 were designed 
using Primer3Plus (Untergasser et al., 2007).   Primer sequences are given in B.1 Human 
PAX6 and TEAD1 validation primers.  Both products were amplified using HotStarTaq 
(Qiagen) with a touchdown from 64 C to 58 C over the first seven cycles and all further 
cycles annealing at 58 C.  Amplified products from all family members were Sanger 
sequenced by Genewiz (South Plainfield, NJ) to confirm variant authenticity and 
transmission. 
2.1.1.7 Predictions of variant functional effects 
In silico functional evaluation was performed for 30 variants in eight core PCP 
genes (CELSR1, DAAM1, DVL1/2/3, LRP6, VANGL1/2) and two transcription factors 
involved in neural tube development (PAX6, TEAD1).  Scores from dbNSFP 2.0 were 
used for functional analysis of the sole missense variant, including scoring by Polyphen-
2, SIFT, MutationTaster, MutationAssessor, and Likelihood Ratio Test (Liu et al., 2013).  
For all SNPs, we evaluated potential impacts on gene splicing, modeling our approach 
after that of Houdayer et al. (Houdayer et al., 2008).  Briefly, splice site prediction 
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utilities NNSplice (Reese et al., 1997), ASSP (Wang and Marín, 2006), and NetGene2 
(Hebsgaard et al., 1996) were used to predict splice sites within 100 nt of each SNP for 
both reference and variant alleles.  Real and predicted splice sites were additionally 
scored using MaxEntScan under the Maximum Entropy model (Yeo and Burge, 2004).   
Variants with a change in score of 10% by any predictive utility were considered 
candidates for affecting splice site function.  Additionally, Human Splicing Finder 
(HSF), which aggregates predictions from a number of tools (Desmet et al., 2009), was 
used to identify potential impacts upon putative splice sites and regulatory motifs 
within 25 nt of each SNV.  Finally, likelihood of effect was scored for all variants using 
Spliceman (Lim and Fairbrother, 2012) and for exonic variants only with MutPredSplice 
(Mort et al., 2014).  Results from all in silico tools were combined into best-estimate 
predictions of each SNV’s possible functional effect. 
2.1.2 Results 
2.1.2.1 Sequence coverage and alignment quality 
All samples showed excellent alignment to reference (Table 2).  On-target 
percentages varied due to difference in shearing parameters, as evidenced by insert 
sizes, but most samples had good coverage of target intervals nonetheless.  Less input 
DNA was available for affected A3, leading to lower coverage for that sample.  
Conversely, the unaffected was oversequenced (150 million raw reads vs. less than 100 
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million for other samples), and its greater duplication rate can be ascribed in part to the 
capture of duplicate fragments.  All samples were very similar in base quality per cycle, 
read quality, sequence content, and GC content as reported by FastQC (Andrews, 2010) 
(data not shown). 
Table 2.  Overview of human exome coverage metrics.  “Target” intervals 
defined as probe locations +/- 200 nt. 
Sample Mapped  Duplicate  On Target 
Mean Target 
Coverage 
Mean 
Insert Size 
M 99% 19% 82% 18x 182 
F 99% 11% 63% 33x 272 
A1 99% 7% 64% 26x 278 
A2 99% 10% 64% 30x 267 
A3 99% 22% 97% 12x 223 
U 99% 43% 86% 35x 202 
 
2.1.2.2 Segregation of homozygous variants with phenotype 
We found a total of 16 rare (MAF<5%) or nonsynonymous variants at which 
homozygosity segregated with phenotype (Table 3Table 1).  Many were associated with 
odorant or taste receptor genes.  None were associated with genes likely to play roles in 
neural tube closure. 
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Table 3. Rare and nonsynonymous variants at which homozygosity segregated with 
affection status.  AAF, alternate allele frequency; PP2, Polyphen-2. 
SNP Gene Class AAF PP2 Score PP2 Rank 
rs17868323 UGT1A7 nonsyn 56% 0.00 benign 
rs9324624 ARHGEF37 nonsyn 48% 1.00 probably damaging 
rs182152607 SSPO intronic 1% --- --- 
rs35083184 OR4A5 nonsyn 12% 0.63 possibly damaging 
rs11246609 OR4C46 nonsyn 58% 0.00 benign 
rs2278108 CLP1 upstream 6% --- --- 
rs1193851 PCNXL3 nonsyn 34% 0.98 probably damaging 
rs10772420 TAS2R19 nonsyn 50% 0.00 benign 
rs17277522 OR6S1 nonsyn 45% 0.99 probably damaging 
rs11622969 OR6S1 nonsyn 54% 0.09 benign 
rs11622794 OR6S1 nonsyn 55% 0.02 benign 
rs9624 TPPP2 nonsyn 12% 1.00 probably damaging 
rs9890664 OTOP3 nonsyn 67% 0.00 benign 
rs4071641 C17orf99 nonsyn 56% 0.00 benign 
rs3744793 USP36 nonsyn 43% 0.01 benign 
rs524625 ANKRD5 nonsyn 26% 1.00 probably damaging 
 
2.1.2.3 Segregation of parental haplotypes with phenotype 
We identified no potential candidate genes in which both parental haplotypes 
segregated with phenotype.  However, several PCP genes (DAAM1, DVL2, and DVL3) 
showed segregation of one parental haplotype with affection status.  As PCP signaling is 
known to be critical to neural tube development and closure, we went on to examine 
other planar cell polarity genes for additional potentially interacting variants. 
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2.1.2.4 Multiple heterozygosity across PCP genes 
We observed no set of variants of different parental origin within any one gene 
that segregated perfectly with phenotype.  However, we did identify a substantial 
number of variants within key PCP genes in the affecteds (Table 4).  Affecteds A1 and 
A2 both inherited a majority of variants, including rare variants from each parent.  
Affected A3 inherited only maternal rare variants, but received many common variants 
from both parents.  Conversely, the unaffected inherited fewer PCP variants overall.  
Most strikingly, all affecteds had variants of different parental origins in at least two 
individual PCP genes, while the unaffected showed no such compounding. 
Table 4. Multiple heterozygosity for SNVs in PCP genes.  AAF, alternate allele 
frequency; MS, missense; SG, stopgain; S, synonymous; het, heterozygous genotype;  
---, homozygous reference. 
Gene SNP Region AAF M F A1 A2 A3 U 
CELSR1 rs1807585 intron 84% --- het --- het --- het 
CELSR1 rs9616008 intron 9% het --- het het --- --- 
CELSR1 rs3747252 intron 13% --- het --- het --- het 
DAAM1 rs1253006 intron 18% --- het het --- het het 
DAAM1 rs8022614 exon (S) 39% het --- het het het --- 
DAAM1 rs61984495 intron 16% --- het --- het --- --- 
DAAM1 rs17096091 intron 16% --- het --- het --- --- 
DAAM1 rs941883 intron 64% --- het het --- het het 
DAAM1 rs941884 exon (S) 64% --- het het --- het het 
DAAM1 rs2146012 intron 82% --- het het --- het het 
DVL1 rs149812757 intron 1% --- het het het --- --- 
DVL1 rs148991554 intron 2% het --- het het het het 
DVL1 rs3855955 intron 29% het --- het het het het 
DVL2 rs72839770 intron 35% --- het het het het --- 
DVL2 rs2074216 exon (S) 36% --- het het het het --- 
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DVL3 rs147410100 intron 1% het --- het het het --- 
LRP6 rs1012672 exon (S) 7% het --- het het het het 
LRP6 rs140962861 exon (MS/SG) 0.01% --- het het het --- --- 
LRP6 rs2075241 intron 18% --- het het het --- --- 
VANGL1 rs3700672727 exon (S) 0.01% --- het het het --- het 
VANGL2 rs116152559 5’ UTR 1% --- het --- het --- het 
VANGL2 rs17371401 intron 25% --- het het --- het --- 
VANGL2 rs140848403 exon (S) 0.4% het --- het --- het --- 
VANGL2 rs12087593 intron 27% --- het het --- het --- 
VANGL2 rs17380127 exon (S) 26% --- het het --- het --- 
VANGL2 rs17380141 exon (S) 26% --- het het --- het --- 
  
heterozygous sites 7 19 21 17 16 11 
  
pct heterozygous 27% 73% 81% 65% 62% 42% 
 
Of variants in these genes, only one altered protein sequence:  rs140962861 in 
LRP6, with a minor allele frequency of 0.01% according to the US National Institutes of 
Health Heart, Lung and Blood Institute-sponsored Exome Sequencing Project (ESP) 
(Fu et al., 2013).  This variant results in either an Arg 1136 > Trp amino acid substitution 
or a stopgain depending on transcript isoform, and was rated deleterious by four 
prediction utilities (Polyphen-2, SIFT, MutationTaster, and MutationAssessor).   
2.1.2.5 Novel heterozygous variants in PAX6 and TEAD1 
We also identified two novel variants, both heterozygous, in transcription factors 
PAX6 and TEAD1.  These are both established NTD candidate genes: Pax6 mutant mice 
can exhibit exencephaly (Cattanach et al., 1996), as do Tead1/2 doubly-null mice (Sawada 
et al., 2008).  Both variants were validated by Sanger sequencing (data not shown; 
primers in B.1 Human PAX6 and TEAD1 validation primers).  The PAX6 variant was 
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transmitted to all three affecteds but not the unaffected, while the TEAD1 variant allele 
was transmitted to A3 and the unaffected. Though the TEAD1 variant did not segregate 
with phenotype, it may be a contributing factor in A3. 
2.1.2.6 In silico predictions of variant functional effects 
Of the 30 variants examined, 20 (67%) variants examined coincide with potential 
TF motifs, while 26 (87%) coincide with potential enhancer elements and could have 
some effect on expression of their associated genes.   Seven variants are predicted by at 
least one of NNsplice, ASSP, NetGene2, MaxEntScan, or Human Splicing Finder to 
strengthen cryptic splice sites, while two are predicted to weaken known splice sites 
(Table 5). 
Table 5. Predicted score changes for cryptic splice sites in proximity to variants. 
SNP Gene Dist Type NNS ASSP NG2 MaxEnt HSF 
rs2074216 DVL2 +6 Acceptor +26% --- --- -4% --- 
rs2074216 DVL2 +18 Acceptor +32% --- --- -41% --- 
rs1012672 LRP6 +0 Donor --- --- --- --- +67% 
rs8022614 DAAM1 +2 Acceptor --- --- --- --- +71% 
rs10500764 TEAD1 +10 Acceptor --- +20% --- +75% --- 
rs17380127 VANGL2 +12 Acceptor --- --- --- +79% --- 
 
All variants were predicted to affect some splicing-regulatory motif in some 
fashion.  In total, 6 of 9 exonic variants were predicted to affect an ESS or ESE element, 
with 17 of 20 intronic variants predicted to impact intronic silencing elements.  Notably, 
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exonic variants in this set more often weaken enhancer elements and/or strengthen 
silencers, suggesting they may promote exon skipping, while more intronic variants 
weaken silencer motifs and could promote utilization of cryptic sites.  Variants for which 
potential exon skipping, exon truncation, or intron inclusion could be extrapolated are 
given in Table 6.
  
 
Table 6.  Summary of predicted variant effects on transcript structure. 
SNP Gene Class Alt AF 
Predicted Impact on Sequence 
Features 
Hypothesized Impact on Protein 
rs3747252 CELSR1 intronic 13% 
broken ISS, new predicted 
acceptor 
exon 2 may begin early, stopgain 
rs9616008 CELSR1 intronic 9% new ISS  may skip exon 3, stopgain in exon 5 
rs8022614 DAAM1 syn 39% new ESS 
may skip exon 6, stopgain in exon 7 
may use alternative termination in exon 6 
rs941883 DAAM1 intronic 64% new ISS may skip exon 13, stopgain in exon 14 
rs941884 DAAM1 syn 64% broken ESE may skip exon 13, stopgain in exon 14 
rs148991554 DVL1 intronic 2% new ISS may skip exon 15; truncates at exon 14 
rs2074216 DVL2 syn 36% 2 new predicted acceptors 
may include intron 3, stopgain 
may create aberrant exon 4, stopgain 
rs147410100 DVL3 intronic 1% new ISS, new predicted acceptor 
exon 11 may begin early, stopgain 
may skip exon 11, no frame change 
rs140962861 LRP6 nonsyn 0.01% broken ESE may skip exon 16, no frame change 
rs2075241 LRP6 intronic 18% weakened acceptor may skip exon 16, no frame change 
rs370067272 VANGL1 syn 0.01% broken ESE may skip exon 7, stopgain in exon 8 
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rs116152559 VANGL2 UTR5 1% broken ESE may skip exon 2; no start codon 
rs17380141 VANGL2 syn 26% broken ESE 
may skip exon 8; truncates at exon 7 
may use alternate termination in exon 7 
chr11:31823331 PAX6 intronic --- new ISS may skip exon 7; no frame change 
rs3026384 PAX6 intronic 29% 
broken ISS, new predicted 
acceptor 
 
exon 8 may begin early; stopgain 
may include intron 7, stopgain 
chr11:12946401 TEAD1 intronic --- new ISS may skip exon 11; no frame change 
rs10500764 TEAD1 intronic 32% 
broken ISS, new predicted 
acceptor 
exon 6 may start early, stopgain 
31 
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2.1.3 Discussion 
We found no evidence for a single primary causal variant underlying the 
anencephaly cases in this multiplex family. Instead, we observed an aggregation of 26 
heterozygous variants within eight key planar cell polarity genes (CELSR1, DAAM1, 
DVL1/2/3, LRP6, VANGL1/2), with a core set spanning DAAM1, DVL1, DVL2, DVL3 and 
LRP6 (Table 4).  These findings echo the broader complex etiology of NTDs in human 
populations.  Most notably, the three AN affected individuals all exhibited variants of 
different parental origins in at least two individual PCP genes.  Conversely, the 
unaffected did not inherit variants from different parents within any PCP gene, and also 
inherited fewer PCP variants overall. 
The functional interactions of variants within NTD-relevant genes remain 
relatively understudied.  Evidence does exist to support that genetic defects in PCP 
signaling may compound to critical effect, especially among DVL family members.  It 
has been shown that while only Dvl2-null mice exhibit NTDs in the single-knockout 
case, heterozygous deficiency of Dvl2 or Dvl3 combined with complete knockout of the 
other exacerbates penetrance and phenotype severity (Etheridge et al., 2008; Hamblet et 
al., 2002).  Dvl3 deficiency can similarly compound with deficiency of Vangl2 (Etheridge 
et al., 2008).  Finally, there is functional redundancy among DVL proteins, with each able 
to rescue deficiency of at least one other (Etheridge et al., 2008).  The effects of variants 
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in any given DVL gene are thus mediated by the abundance or deficit of other family 
members; in a case such as this, where variants are present in multiple DVL genes, their 
cumulative effects may overturn the normal functional redundancy of these proteins. 
These variants may further compound with the variants we observed in DAAM1 
and LRP6, both of which are established NTD candidate genes and interact with DVLs.  
A diagram showing the interactions of these genes is given in Figure 4.  DVLs are the key 
mediators of PCP signaling, but DAAM1 is essential for DVL-Rho complex formation 
and downstream activation of RhoA (Habas et al., 2001).  Additionally, although LRP6 is 
best known as a co-receptor for canonical Wnt signaling, it has recently been shown to 
be a necessary part of the DVL-Rho complex as well (Gray et al., 2013).  Finally, VANGL 
family members have an antagonistic interaction with the FZD-DVL complex (Shafer et 
al., 2011) which is also essential for DVL-Rho activity; disruption of VANGL2 has been 
shown to impair RhoA expression and signaling (Phillips et al., 2005).  Variants across 
these genes are likely to have a cumulative effect on RhoA activation PCP signaling, 
even if their effect sizes are individually small.   
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 Figure 4.  Interactions among selected members of the PCP signaling pathway.   
 
In light of these interactions, it is perhaps telling that the unaffected offspring 
from our multiplex family had no compounding of different-origin variants within any 
single one of these genes.  Furthermore, the unaffected inherited no variants in DVL2 or 
DVL3, the two DVL family members most strongly implicated in NTDs.  Conversely, the 
affecteds all exhibited mixtures of parental alleles both across DVL family members and 
within at least two key members of the DVL-Rho complex, which we posit collectively 
depressed PCP signaling below the level necessary for neural tube closure.   
Additional variants in downstream effectors or essential transcription factors 
such as PAX6 and TEAD1, both of which contained novel variants in this family, may 
have further compounded this deficit.  PAX6 defines the future forebrain (Mastick et al., 
1997) and is a marker for the dorsal neural tube regulated by Wnt signaling (Alvarez-
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Medina et al., 2008).  TEAD1 is a regulator of cell proliferation (Sawada et al., 2008) and 
a target of Hippo signaling, which crosstalks with both Wnt and Hedgehog signaling 
throughout development (Zhao et al., 2010).  These variants are good candidates for 
additional interactors that may have contributed to the development of AN in this 
family. 
Most of the variants we identified were synonymous or intronic, for which 
functional repercussions are difficult at best to predict.  Nearly all of our variants were 
proximate to a splice junction, suggesting they may affect transcript splicing. Notably, 
studies of disease-causing mutations in BRCA1 (Liu et al., 2001) and ATM (Teraoka et 
al., 1999) suggest that as many as 50% of deleterious variants impact transcript structure, 
whether through directly affecting a splice site or by altering regulatory motifs.  We did 
not have RNA available for this family and could not directly interrogate transcript 
structures.  Instead, we used existing in silico utilities to predict effects on splice site 
recognition.  We found these utilities to perform especially poorly with regard to donor 
sites.  Although all utilities predicted roughly equal numbers of acceptors and donors 
within sequences, only half of real donor sites were identified in these genes, and those 
only by one utility (ASSP).  Conversely, 85% of real acceptors were identified, most by 
all three utilities.  This has poor implications for the ability of these tools to predict the 
impact of sequence variation on donor site recognition.  We also were not able to predict 
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early termination of transcripts, though several variants are near alternative termination 
sites.   
With the in silico utilities we used, two of our variants were predicted to 
negatively impact existing splice sites, while five were predicted to enhance potential 
cryptic splice sites (Table 6).  In total, 6 of 9 exonic variants may promote exonic 
skipping through their effects on splicing regulatory motifs, including one which also 
weakened an existing acceptor, while 13 of 20 intronic variants may break intronic 
silencing elements, including 3 which also create potential cryptic splice sites (Table 6).  
Furthermore, most variants coincided with any of a number of TF binding motifs, and 
nearly all variants were located in potential enhancer elements, suggesting a potential 
for effects on expression even for variants that may not impact splicing.  Ultimately, the 
functional effects of these variants can only be conclusively determined by examining 
transcript structure and expression levels of the associated genes.  This is a critical aspect 
to be studied in the future, along with follow-up studies in larger cohorts, particularly 
focusing on total variant burdens across genes and pathways and addressing potential 
gene-gene interactions in NTD etiology.     
 Because the DNA for all the affecteds was derived from tissue from pregnancy 
terminations, an additional challenge in this analysis was maternal DNA contamination 
of affected A2.  We found that increasing the contamination parameter in 
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UnifiedGenotyper successfully corrected the majority of variants.  Miscalled sites that 
remained were sporadic, with few to none in any given gene; these we addressed by 
comparing haplotypes instead of individual variants, permitting a proportion of 
mismatches, and manually curating the resultant hits.  This approach is robust against 
false negatives, though the standard caveat remains that a critical variant may have been 
located outside the regions exome sequencing covers.  However, in this multiplex 
pedigree, we would expect any such variant to have a large effect and most likely occur 
in the coding region of a candidate gene, precisely what exome sequencing is suited to 
detect.  These data underscore the importance of characterizing genetic background and 
genetic interactions even in multiplex families. 
2.2 Genetic background as a modifier of NTD risk: evidence from 
a mouse model 
In mouse models of NTDs, genetic background has been shown to influence 
NTD phenotype and penetrance.  Examples include knockout of the gene Men1, which 
produces NTDs in 129S6/SvEv but not in C57BL/6 (Lemos et al., 2009), and differential 
phenotypes for crosses of the splotch mutation onto other strain backgrounds (Fleming 
and Copp, 2000).  Genetic variants may additionally mediate environmental risk factors; 
most strikingly, mouse studies indicate that folate deficiency only causes NTDs when 
combined with a predisposing genetic background (Burren et al., 2010; Heid et al., 1992).   
Conversely, studies have also demonstrated that folate supplementation increases NTD 
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risk in some mouse models (Marean et al., 2011), an effect which may be particularly 
important to investigate in this era of mandatory fortification. 
The role of genetic background in modifying NTD risk is strongly illustrated by 
the LM/Bc and SWV mouse strains, described in the previous chapter (Section 1.5).  For 
this study, we focused on modifiers affecting susceptibility to FB1-induced NTDs in the 
LM/Bc strain.  Fumonisins are competitive inhibitors of ceramide synthases 
(Section 1.4.2.2), which function in de novo sphingolipid biosynthesis (Figure 5), 
producing ceramide from simple sphingolipids such as sphingosine (So) and 
sphinganine (Sa).  In the presence of fumonisin, levels of ceramide are depleted and 
simple sphingolipids become more abundant, particularly Sa. 
 
Figure 5. Overview of ceramide metabolism. 
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Ceramide derivatives are important components of lipid rafts that anchor 
membrane-bound receptors, including the folate receptor FOLR1.  Indeed, experimental 
evidence shows that FB1-induced NTDs in LM/Bc embryos can be partially prevented 
with supplemental folic acid, and almost completely rescued with supplemental 
ganglioside GM1 (Gelineau-van Waes et al., 2005).  However, the genetic factor or 
factors that underlie the strain’s sensitivity to FB1 remain unknown.  Here we use exome 
sequencing to identify variants in LM/Bc that are distinct from the SWV strain and may 
promote susceptibility to fumonisin-induced NTDs. 
2.2.1 Methods 
2.2.1.1 Exome library preparation, sequencing, and alignment 
DNA from tail snips of representative LM/Bc and SWV mice, extracted using the 
Wizard Genomic DNA Purification Kit (Promega Corporation, Madison, WI), was 
provided by the Gelineau-van Waes lab.  Exonic regions were enriched for one mouse of 
each strain using the SureSelect XT Mouse All Exon kit (Agilent Technologies, Santa 
Clara, CA), according to manufacturer’s recommendations.  This kit targets 221,784 
exons within 24,306 genes, with a total capture size of 49.6 MB.  Prepared libraries were 
sequenced 2x100nt on an Illumina HiSeq at the David H. Murdock Research Institute.  
The resulting data was aligned against the NCBI37 mouse reference genome, the 
alignments cleaned, and variants called as previously described, except without use of 
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the contamination threshold parameter or allele phasing.  Variants were annotated 
against mouse RefSeq genes as previously described.  To reduce artifacts and false 
positives, variants were restricted to a read depth of at least 4, fewer than 10% of reads 
with mapping quality of 0, and a quality-by-depth of at least 7.  Only sites homozygous 
for different alleles in LM/Bc and SWV were included in analyses.   
2.2.1.2 Sanger validation of variants in Cers1-Gdf1 
Primers were designed using Primer3Plus (Untergasser et al., 2007) to encompass 
the entire exon 8 of Cers1-Gdf1, with a nested sequencing primer; sequences are given in 
Appendix B: Primer Sequences.  Primer oligos were ordered from Integrated DNA 
Technologies (Coralville, IA).  Target regions were amplified using HotStarTaq DNA 
polymerase (QIAGEN, Germantown, MD) and sequenced on a 3730 DNA Analyzer 
using BigDye chemistry (Life Technologies, Carlsbad, CA).  Variants were sequenced in 
both directions and in two mice of each strain. 
2.2.1.3 Analysis of exome variants from AKR/J genome data 
From the Mouse Phenome Database (Grubb et al., 2014), we determined the 
AKR/J strain shared the LM/Bc genotypes of sites in Gdf1.  The Gelineau-van Waes lab at 
Creighton University also determined experimentally that AKR/J mice have moderate 
susceptibility to FB1-induced NTDs (see Section 2.2.3).  To further evaluate genetic 
concordance between these strains, AKR/J whole-genome sequence data aligned to 
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GRCm38 was downloaded from the Wellcome Trust Sanger Institute Mouse Genomes 
Project (Yalcin et al., 2012).   Exome target intervals were converted to GRCm38 
coordinates using the liftOver webtool, and variants called over these regions as above.  
For analysis, variants were constrained on genotype as above, also requiring 
homozygous genotypes in AKR/J. 
2.2.2 Results 
2.2.2.1 Mouse exome sequence alignment 
Both mouse exomes showed excellent alignment to reference (Table 7), low 
duplication rates, and high coverage of target regions.  Both were also very similar in 
base quality per cycle, read quality, sequence content, and GC content as reported by 
FastQC (Andrews, 2010)  (data not shown). 
Table 7.  Alignment metrics for mouse exome sequence data.  Target interval defined 
as bait +/- 100 nt. 
 
Mapped Duplicated On Target Mean Target Coverage 
LM/Bc 99% 8% 71% 108x 
SWV 99% 10% 70% 113x 
 
2.2.2.2 Overview of genetic differences between LM/Bc and SWV mouse strains 
A total of 362,528 variants were called from the exome data, of which 264,616 
(73%) passed quality filters.  Half of filtered variants (132,510) were homozygous and 
discordant between the two strains; LM/Bc was non-reference at 44% of those sites 
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(58,357), encompassing 4,256 genes.  In total, 129 Gene Ontology (GO) biological process 
(BP) terms were found to be significantly enriched for these genes using g:Profiler 
(Reimand et al., 2011) with g:SCS multiple testing correction. The best-per-parent 
summarization of these enrichments is given in Table 8.   
Table 8.  Per-parent GO BP term enrichments for genes with variants in the LM/Bc 
strain.  P values were corrected for multiple testing using g:SCS. 
p-value Term Name Term ID Genes 
2.24e-40 single-organism process GO:0044699 2555 
3.46e-37 cellular process GO:0009987 2728 
1.84e-17 regulation of cellular process GO:0050794 1821 
2.41e-17 metabolic process GO:0008152 1910 
4.01e-16 localization GO:0051179 974 
4.99e-11 multicellular organismal development GO:0007275 855 
2.42e-10 cellular component organization or biogenesis GO:0071840 897 
1.14e-08 signaling GO:0023052 1146 
7.98e-08 signal transduction GO:0007165 1063 
3.29e-03 smoothened signaling pathway GO:0007224 38 
2.39e-02 regulation of protein kinase activity GO:0045859 127 
3.44e-02 regulation of insulin secretion GO:0050796 41 
 
Most enriched terms are broad metabolic, developmental, or cell communication 
processes, as the per-parent summary indicates.  However, two specific enriched terms 
are notable:  smoothened signaling pathway (p=3.29e-03), synonym of Hedgehog 
signaling, and nervous system development (p=6.01e-05).  Although neural tube closure 
was not a significantly enriched term, many genes involved in neural tube 
morphogenesis and closure contribute to other aspects of nervous system development.  
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These findings suggest that LM/Bc is particularly distinct from SWV and from reference 
in genes relating to nervous system development.   
2.2.2.3 Nonsynonymous variants in Cers1-Gdf1 
Individually, the most notable sites were two missense variants in the Cers1-Gdf1 
bicistronic transcript (Table 9).  Both are located in exon 8, in the pro-domain region of 
GDF1.  These variants were validated by Sanger sequencing (data not shown).  
Functional impacts of amino acid substitutions were scored with Polyphen-2.  As an 
additional indicator of effect, prevalence of the LM/Bc alleles across mouse strains was 
determined using the Mouse Phenome Database standard SNP variation query. 
Table 9.  Nucleotide and amino acid changes for variants in Cers1-Gdf1. 
 
Reference LM/Bc SWV 
Prevalence of 
LM/Bc allele Polyphen-2 score 
rs32650885 
A 
serine 
A 
serine 
T 
cysteine 
9/17 strains 
(52%) 
benign  
(0.00) 
rs47220823 
G 
alanine 
A 
threonine 
G 
alanine 
1/23 strains 
(4%) 
possibly damaging 
(0.66) 
 
2.2.2.4 Summary of variants associated with sphingolipid metabolism genes 
Of variant sites in LM/Bc not shared by SWV, a total of 271 were associated with 
sphingolipid metabolism genes, summarized by gene in Table 10.  Particularly notable 
genes include Degs2 (14 variants), Acer2 (3 variants), Acer3 (50 variants), Cerk (2 
variants), and Ppap2a (3 variants); refer to Figure 5 for their roles in sphingolipid 
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biosynthesis.  Although none of these variants were nonsynonymous, some may have 
regulatory and/or splicing effects that contribute to the strain’s sensitivity to fumonisin.   
Table 10.  Summary by gene of LM/Bc-specific variants in sphingolipid metabolism 
genes.  In parentheses are counts of nonsynonymous and total variants. 
Acer2 (0/3) Acer3 (0/50) Aldh5a1 (1/51) 
Arsi (1/11) Cerk (0/2) Cers5 (1/11) 
Cers6 (0/5) Degs2 (0/14) Gba2 (1/2) 
Hexa (0/11) Kdsr (0/2) Naga (0/11) 
Neu3 (3/23) Ppap2a (0/3) Ppm1l (0/13) 
Ppt1 (0/7) Prkaa1 (0/1) Smpdl3b (1/3) 
St8sia2 (0/33) St8sia3 (0/1) Sumf1 (0/14) 
 
2.2.2.5 Summary of variants in genes associated with neural tube phenotypes 
Of variants in LM/Bc but not SWV, 2,467 sites were distributed across 134 genes 
associated with either abnormal neural tube morphology or exencephaly.  The ten 
phenotype genes with the greatest number of discordant variants are given in Table 11.  
Notably, these include Wnt signaling co-receptors Lrp2 and Lrp6.  Phenotype genes not 
making the top ten overall, but containing high numbers of nonsynonymous variants 
are Brca1 (9 NS, 22 total), Fat4 (6 NS, 32 total), and Hoxb2 (4 NS, 11 total).  These genes 
and variants may be good candidates for modifiers affecting LM/Bc sensitivity to 
fumonisin. 
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Table 11.  Summary of the top ten genes with variants in LM/Bc not shared by SWV.  
*All exonic variants in C2cd3 annotated as amino acid substitution ‘unknown’.  
Gene Variants NS Syn Intronic 5’UTR 3’UTR 
Pdgfrb 154 3 18 133 0 0 
C2cd3* 148 --- --- 115 0 0 
Tenm4 148 3 39 104 1 1 
Gtf2i 128 0 9 119 0 0 
Lrp2 127 5 10 112 0 0 
Tcof1 118 18 9 89 1 0 
Lrp6 114 5 10 98 0 1 
Bbs7 112 4 14 85 1 7 
Itga3 110 3 17 87 0 3 
Tiam1 89 2 9 78 0 0 
2.2.2.6 Concordance of LM/Bc variants with AKR/J genotypes 
Of variants in LM/Bc but not SWV, 57,850 sites were also called homozygous for 
any allele in AKR/J.  AKR/J shared the LM/Bc allele at 22,814 (39%) of these sites, and 
possessed a different allele at 35,036 (61%) sites (Table 12). 
Table 12.  Summary of LM/Bc concordance with AKR/J at variants not in SWV. 
 All Neural Tube Exencephaly Sphingolipid Combined 
Concordant Genes 1,892 50 25 8 67 
Concordant Vars. 22,814 830 826 55 1,382 
Discordant Genes 2,854 72 42 14 99 
Discordant Vars. 35,036 1,129 445 216 1,380 
 
Across genes of interest, the number of concordant variants essentially equaled 
the number of variants not also found in AKR/J.  However, discordant variants did not 
follow the same distribution across these gene sets; particularly, there were more 
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discordant variants in sphingolipid metabolism genes, including Acer2 (3 variants), 
Acer3 (50 variants) and Cerk (2 variants).  Discordant sites were also more numerous 
across neural tube morphology genes, including Celsr1 (48 variants), Fzd1 (4 variants), 
Gli2 (1 variant), Smo (1 variant), Folr1 (16 variants), Dnmt1 (59 variants), and Tead1 
(11 variants).  Interestingly, variants in TEAD1 also showed significant association with 
sphingolipid metabolite levels in our related human study (Section 4.2.2.2).  Tead1 
variants and others not shared by SWV or AKR/J mice are among the most likely to 
promote the greater susceptibility of LM/Bc embryos to FB1-induced NTDs. 
2.2.3 Discussion 
Exome sequencing of fumonisin-susceptible and -resistant mouse strains 
identified 132,510 homozygous sites with different alleles in the LM/Bc and SWV mouse 
strains.  At 44% of those sites, LM/Bc had a non-reference allele; these 58,357 variants are 
candidate modifiers that may promote sensitivity to FB1-induced NTDs.  Conversely, 
some among the 74,269 sites where SWV had a non-reference allele are likely to inform 
that strain’s susceptibility to NTD-inducing teratogens other than fumonisin; however, 
analysis of those variants is beyond the scope of this thesis. 
As fumonisins are competitive inhibitors of ceramide synthase, the two 
discordant, nonsynonymous variants in Cers1-Gdf1 are of particular interest (Table 9).  
This gene is a bicistronic transcript (Figure 6A) which produces ceramide synthase 1 
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from the 5’ end (exons 1-7) and growth and differentiation factor 1, a TGF-β family 
ligand, from the 3’ end (exons 7-8).  As other TGF-b family members, GDF1 contains a 
signal peptide, a pro-domain, and the active domain (Figure 6B) which is cleaved into 
the mature protein (Kingsley, 1994).  After cleavage, the pro-domain peptide may form a 
complex with the mature protein, continuing to inhibit signaling.   
 
 
 
Both of our missense variants are located in the pro-domain, and we hypothesize 
that the resultant amino acid differences may affect complex stability.  Specifically, the 
cysteine residue in SWV may form a disulfide bond which, along with the hydrophobic 
alanine at the second site, promotes association.  Conversely, the LM/Bc alleles code for 
polar acids serine and threonine that may promote complex disassociation and increase 
GDF1 activity.  Gdf1 knockout has been shown to increase Cers1 expression (Bengtsson 
et al., 2008); accordingly, increased GDF1 activity can be expected to decrease CERS1 
Figure 6. Location of strain-specific missense variants within A) Cers1-Gdf1 
bicistronic transcript and B) GDF1 protein structure. 
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abundance, increasing susceptibility to the effects of fumonisin.  In situ hybridizations 
performed by the Gelineau-van Waes lab show that exencephalic FB1-treated LM/Bc 
embryos have increased expression of Gdf1 at E9.5 relative to controls (data not yet 
published), supporting this hypothesis. 
Through the Mouse Phenome Database, we identified a second mouse strain, 
AKR/J, which shared alleles with LM/Bc at both Gdf1 variant sites.  The Gelineau-van 
Waes lab has performed fumonisin exposure experiments in this strain, and observed a 
20% incidence of NTDs in AKR/J under the same conditions which produce 79% NTDs 
in LM/Bc (data not yet published).  Exencephalic FB1-treated AKR embryos also show 
increased Gdf1 expression by in situ hybridization, though not as strongly as their LM/Bc 
counterparts (data not yet published).  These data indicate that these Gdf1 variants 
contribute to but do not fully explain the susceptibility of LM/Bc mice to FB1-induced 
NTDs.   
To identify other potential genetic modifiers of susceptibility to FB1, we 
contrasted our LM/Bc exome data with the Mouse Genome Project AKR/J genome.  
Interestingly, when considering only sites with different alleles in LM/Bc and SWV, we 
observed more discordance than concordance between LM/Bc and AKR/J in genes 
associated with sphingolipid metabolism and abnormal neural tube morphology (Table 
12).  Of particular note is Folr1, which contained 16 variants in LM/Bc not shared by 
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AKR/J.  Some of these may act to reduce FOLR1 abundance; that FB1-induced NTDs can 
be rescued by folate suggests depletion of FOLR1 would increase susceptibility.  This 
also echoes existing literature on the interactions between genetic background and folate 
deficiency as an NTD risk factor (Burren et al., 2010).  Other variants in components of 
sphingolipid metabolism (Acer2, Acer3, Cerk), Wnt signaling (Celsr1, Fzd1), and 
Hedgehog signaling (Gli2, Smo), are also likely candidates for increasing susceptibility in 
the LM/Bc strain beyond that of AKR/J and SWV. 
2.3 Conclusions: the multiple roles of genetic risk factors in NTD 
etiology 
 Genetic factors are an unquestionably strong component of NTD etiology.  Loss 
of function of one gene may be sufficient to cause NTDs, as is seen in most mouse 
models.  Alternately, NTD phenotypes may arise from interactions of lesions across 
multiple genes, as described by the oligogenic model generally accepted for human 
NTDs; our data indicate this to be the mechanism at work in the multiplex family 
described above (Section 2.1).  Most importantly, we document that a combination of 
rare and common alleles, as opposed to rare variants or putative mutations with large 
effect sizes, may underlie NTD pathogenesis even in highly penetrant NTDs.  The 
contributions of common variants and cumulative effect to human NTD pathogenesis 
remain generally understudied, and our findings underscore the importance of 
characterizing these in human NTD research. 
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Genetic risk factors also may not be sufficient to cause NTDs in and of 
themselves, but create a permissive background in which an environmental risk factor 
supplies the “second hit”.  This is most readily demonstrated with animal models, such 
as the differential sensitivities to FB1 we observed between LM/Bc, AKR/J, and SWV 
mice (Section 2.2).  The contributions of fumonisins to human NTD pathogenesis remain 
to be determined but, combined with the human SNP association study in Section 4.2, 
our findings indicate that genetic background modulates the effects of FB1 in both mice 
and humans.  These data demonstrate a need for further elucidation of gene-
environment interactions in human NTD etiology, not only in the context of FB1, but for 
other environmental risk factors as well. 
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Chapter 3:  Altered DNA methylation as a potential 
contributor to the etiology of human NTDs 
At the interface between genes and environment, epigenetic marks, particularly 
DNA methylation, have recently become a key topic in NTD research.  Folic acid, the 
only known preventative agent for NTDs, is an essential cofactor for methylation 
reactions (Beaudin and Stover, 2009).  Deficiencies of other methylation cofactors, 
namely methionine (Shoob et al., 2001) and vitamin B12 (Ray et al., 2007), have also been 
implicated in NTD risk, while histone deacetylase inhibitors such as valproic acid can 
cause NTDs (Eikel et al., 2006).  Simple sphingolipids, which are increased by fumonisin 
exposure, have also been identified to act as histone deacetylases (Hait et al., 2009).   
The expression patterns of DNA methyltransferases 3a and 3b (Dnmt3a, Dnmt3b) 
in mouse embryos around the time of neural tube closure also have suggestive 
implications.  Dnmt3b is strongly expressed in the very early embryo, but is replaced by 
Dnmt3a around E8.5-E10.5 (Okano et al., 1999; Watanabe et al., 2002), just before and 
during the time of neural tube closure. Around that time, Dnmt3b is expressed in neural 
ectoderm and the future forebrain, with Dnmt3a being ubiquitous; both are present in 
the embryonic ectoderm (Okano et al., 1999).  Although Dnmt3a knockout mice gestate 
normally, Dnmt3b knockouts show normal development only prior to E9.5, with 
subsequent growth impairment and cranial neural tube defects (Okano et al., 1999).  This 
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suggests that errors in DNA methylation, particularly at very early developmental 
stages, may indeed contribute to failure of neural tube closure. 
Taken together, these relationships suggest a link between perturbed DNA 
methylation and NTD etiology.  Slight but significant global hypomethylation has been 
observed in the in brain tissue of NTD cases, and the degree of hypomethylation may 
correlate with NTD phenotype severity (Chen et al., 2010).  A second study documented 
significantly perturbed distributions of genomic methylation between cases and controls 
in multiple tissues (Chang et al., 2011).   However, no functional evidence connecting 
altered DNA methylation with NTD etiology has been documented as of yet.  It remains 
to be determined whether changes in methylation contribute directly to NTD 
development or are a side-effect of aberrant developmental processes. 
3.1 Differential methylation in a monozygotic twin pair 
discordant for anencephaly 
To reduce confounding variables, we selected a monozygotic (MZ) twin pair 
discordant for AN for this study.  These twins were expected to be genetically identical, 
based on their MZ status, and had no observed in utero complications which might have 
contributed to the defect phenotype; thus, they provided an excellent context in which to 
identify possible relationships between DNA methylation and anencephaly.  We 
performed exome sequencing and whole-methylome profiling on both twins, and 
included their parents and an unaffected sibling in validation experiments.  
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3.1.1 Methods 
3.1.1.1 Sample collection and clinical information 
This twin pair was selected for study because of their monozygotic twin status, 
implying identical genetics, combined with phenotypic discordance for anencephaly.  
They were collected as participants in the Hereditary Basis of Neural Tube Defects study 
as described in Chapter 2.  Relevant clinical information is given in Table 13.  Cord 
blood was collected immediately following delivery of the twins, both of which were 
live-born, and DNA was extracted by the Duke University DNA Bank and Tissue 
Repository using PureGene chemistry on a Qiagen Autopure instrument (Qiagen, 
Germantown, MD). 
Table 13.  Clinical details for the MZ twin pregnancy. 
Twin pair gender Female 
Parental ethnicity Caucasian 
Maternal BMI category Normal 
Prenatal supplement use Yes, pre- and post-conception 
Relevant maternal exposures Consumed wine and liquor pre-
conception, smoked occasionally (<1 
cigarette per day), took Claritin, used a 
hot tub pre- and post-conception, had 
mononucleosis just prior to conception. 
 
3.1.1.2 Exome sequencing and analysis 
Extracted DNA was sheared to 200 nt on a Covaris S2 Adaptive Focused 
Acoustic Disruptor and enriched for coding regions using the SureSelect Human All 
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Exon kit (Agilent Technologies, Santa Clara, CA) according to manufacturer’s directions.  
Exome fragments were sequenced on an Illumina HiSeq as 100 nt paired-end reads.  
Reads were aligned to the NCBI human genome build 37.1, alignments refined, and 
variants called as previously described (Sections 2.1.1.3, 2.2.1.1).  Only variants with a 
quality score of at least 50, a depth of at least five reads in each sample, and a minimum 
quality-by-depth score of 10 were included in analysis.  Variant sites were mapped to 
their corresponding RefSeq and Ensembl genes using ANNOVAR (Wang et al., 2010) 
with a neargene threshold of 2 kb. 
3.1.1.3 Methylation profiling by MBD-seq 
Extracted DNA was sheared as above and enriched for methylated regions using 
the MethylMiner kit (Life Technologies, Grand Island, NY).  Captured fragments were 
sequenced on an Illumina HiSeq as 100 nt single-end reads.  Image analysis, base calling, 
alignment to the human genome build 37.2, and alignment cleaning were performed as 
above.  Picard was used to determine read depths over all CpGs queried by the 
HumanMethylation450 microarray.  Model-based Analysis for ChIP-Seq (MACS) was 
used to identify DMRs significant at p=1e-05 (Zhang et al., 2008).  DMRs were annotated 
as for SNVs. 
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3.1.1.4 Methylation profiling by HumanMethylation450 array 
Genomic DNA was bisulfite converted using the EZ DNA Methylation Kit 
(Zymo Research, Irvine, CA) and run on HumanMethylation450 (450k) microarrays per 
the manufacturer's protocol (Life Technologies). Probes were excluded if missing data in 
any sample, if more than 80% of samples had a detection p-value greater than 0.05 for 
that probe, or if the probe had been previously identified as cross-reactive with other 
genomic locations (Chen et al., 2013).  Peak correction was performed using IMA (Wang 
et al., 2012) to normalize the two different types of probes present on the chip.  Color 
channel adjustment and quantile normalization were performed using methylumi (Bilke 
et al., 2012).  Sites with a delta beta of 10% or greater between the twins were considered 
differentially methylated; these sites were annotated against Ensembl 72 genes, as above.  
Term enrichment analysis was performed using the g:Profiler webtool, with the 
developer's recommended g:SCS multiple-testing correction (Reimand et al., 2011).  Sites 
were additionally annotated against ChIP-seq data for AP-2α in HeLa-S3 cells (ENCODE 
Project Consortium, 2011) and CDX2 in proliferating and differentiated Caco-2 cells 
(Verzi et al., 2010).  Both datasets were downloaded from ChIPBase (Yang et al., 2013). 
  A second MZ twin pair, with twin-to-twin transfusion syndrome (TTTS), was 
also included in this experiment for comparison purposes.  These samples were 
collected, extracted, and bisulfite converted as described above. 
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3.1.1.5 Validation of DM sites by Epityper assay and high-throughput bisulfite 
sequencing 
Five DMRs from the MBD-seq data (in CAMTA1, LRP1B, DAAM2, APC, GLI1) 
were selected for validation in the original MZ twin pair by Sequenom EpiTyper assay 
on the basis of potential gene involvement in neural development and regulatory 
features in ENCODE data.   The two most striking DMRs from the 450k data (RAP2B 
and mir-886) were also targeted in this experiment.  Primer design and the EpiTyper 
assay were performed by the David H. Murdock Research Institute Genomics core 
facility according to manufacturer’s protocol.  Primer sequences are given in 
Appendix B.3.1. 
A second validation experiment was performed for additional DMRs in the 450k 
data, selected from genes involved in neural development and also including mir-886.  A 
total of 20 amplicons in 15 genes associated with neural development were assayed by 
high-throughput bisulfite sequencing.  mir-886 was the only target included in both 
validation sets.  Samples used for validation included the original AN and TTTS MZ 
twin pairs, five additional dizygotic (DZ) twin pairs, one set of DZ triplets, parents of all 
sibling sets, and unaffected siblings as applicable.  All sibling sets contained one affected 
proband, and all family members were unaffected.  Methylated and unmethylated 
human DNAs from Zymo Research Corporation, (Irvine, CA) were also included as 
controls.  Primers were designed using MethPrimer (Li and Dahiya, 2002); in regions 
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with high CpG density, settings from MethPrimer were used in Primer3Plus 
(Untergasser et al., 2007) and primers containing a minimum of CpGs selected for use.  
Primers were ordered from Integrated DNA Technologies (Coralville, IA); sequences 
and amplification conditions are given in Appendix B.3.2.   
Samples were bisulfite converted using the EZ DNA Methylation kit (Zymo), 
and amplicons generated using HotStarTaq polymerase (Qiagen, Germantown, MD).  
PCR products were pooled in equal amounts by sample, and sample libraries generated 
using the Nextera XT sample preparation kit (Illumina, Inc., San Diego, CA). Libraries 
were sequenced 2x150nt on an Illumina MiSeq.  Reads were aligned against target gene 
excerpts from the hg19 human reference build using Bismark (Krueger and Andrews, 
2011) and Bowtie 2 (Langmead and Salzberg, 2012).  Due to short amplicon size, 
overlapping read pairs were merged using FLASH (Magoč and Salzberg, 2011) and all 
reads aligned as if they had been single-end sequenced.  Bismark was used to call 
methylation at all covered CpGs.  Only sites covered by at least 35 reads were included 
in analyses. 
3.1.2 Results 
3.1.2.1 Genetic discordance between the twins 
A total of 66,231 SNVs passed quality filters, with at least one SNV present in 
74% of covered Ensembl genes.  The twins had identical genotypes at all sites but one, a 
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novel mutation in the unaffected twin which was not present in any other unaffected 
family members.  This mutation was located in intron three of sedoheptulokinase 
(SHPK), a component of the pentose phosphate pathway (Kardon et al., 2008); to our 
knowledge, neither gene nor pathway has previously been implicated in NTDs.  We 
concluded this sole discordant variant is unlikely to contribute to the twins' different 
phenotypes. 
3.1.2.2 Genetic variants in neural morphology genes 
We identified a total of 2,512 variants for these twins in candidate genes for 
abnormal neural tube morphology (A.1 Genes associated with abnormal neural tube 
morphology in mice) or exencephaly (A.2 Genes associated with exencephaly in mice).  
These included 104 nonsynonymous SNVs and one stopgain SNV (in CASP7, alternate 
allele frequency 59.7%).  Of nonsynonymous variants, 15 were scored possibly 
deleterious by both SIFT and either Polyphen-2 HDiv or HVar (Table 14).  As described 
above, genotypes at these sites were common to both twins. 
Table 14.  Potentially deleterious variants in neural morphology genes, as determined 
by SIFT and Polyphen-2 scores.  AAF, alternate allele frequency; AA, amino acid 
substitution; GT, genotype; PP2, Polyphen-2; GERP, GERP++ Rejected Substitution 
score. 
SNP Gene AAF AA SIFT PP2 HDiv PP2 HVar GERP 
rs3824915 ALX4 --- R35>T 0.01 0.437 0.115 4.61 
rs235768 BMP2 --- R190>S 0.01 0.978 0.871 5.72 
rs16941 BRCA1 66.10% E1038>G 0.04 0.936 0.606 -0.974 
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rs11074359 COQ7 96.10% T65>M 0.02 0.889 0.631 5.91 
rs1110719 ESPL1 --- K1435>M 0.02 0.761 0.275 3.65 
rs1567047 FAT4 --- G3524>D 0.02 1 1 5.77 
rs147788385 FZD6 --- A150>T 0.03 0.99 0.763 5.6 
rs114198341 HES3 1.10% N10>S 0 0.999 0.997 4.51 
rs139475791 HOXB13 15.10% R217>C 0 1 0.999 5.31 
rs944895 LAMA5 99.50% R3079>W 0.01 0.983 0.545 3.38 
rs4667591 LRP2 --- I4210>L 0.03 0.995 0.992 4.5 
rs45478192 PALB2 --- L939>W 0 1 1 5.81 
rs139272770 SHROOM3 --- H207>Y 0 0.999 0.986 6.06 
rs2274924 TRPM6 --- K1579>E 0.03 0.787 0.526 4.64 
rs1432273 TTC21B 88.30% V201>M 0.03 0.992 0.95 2.52 
 
Using Pearson’s chi-squared test, we tested the distributions of exonic vs. 
intronic and non-synonymous (including stopgain and stoploss) vs. synonymous 
variants in candidate gene sets as compared to the twins’ whole-exome background 
(Table 15).  In both abnormal neural tube morphology and exencephaly candidate genes, 
we found significant enrichment for exonic SNVs over intronic relative to the rest of the 
exome, and also for synonymous SNVs over nonsynonymous.  These synonymous 
variants may include alleles with regulatory impact which provided a permissive 
background for NTDs in these twins and sensitized to environmental risk factors. 
Table 15.  Enrichments of variant types in candidate gene sets over whole-
exome background. 
Gene set 
Exonic vs. Intronic Nonsynonymous vs Synonymous 
p-value Enriched p-value Enriched 
NT morphology 4.31e-04 exonic 1.573e-07 synonymous 
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Exencephaly 0.0091 exonic 5.69e-04 synonymous 
Combined 4.71e-05 exonic 1.89e-07 synonymous 
 
3.1.2.3 Agreement of methylation profiling methods 
In terms of the twins' global methylation profile, the MDB-seq and 450k array 
data agreed favorably with one another (Table 16).  Both methods revealed a global 
tendency towards hypomethylation in the affected twin, and interestingly documented 
similar numbers of DM sites and associated genes, although very few individual genes 
were considered differentially methylated by both profiling methods simultaneously.   
Table 16. Global overview of methylation as determined by each profiling 
method. 
 MBD-seq 450k array 
Total DM regions or sites 1,737 1,152 
Hypermethylated sites 45% 34% 
Hypomethylated sites 55% 66% 
Total DM genes 818 805 
Hypermethylated genes 36% 37% 
Hypomethylated genes 67% 63% 
Genes with hyper & hypo sites 3% 1% 
 
MBD-seq reads covered only 36.6% of all sites queried by the 450k array, 
including 58.6% of 450k DM sites in this twin pair.  Of those, 62.4% showed a difference 
in MBD-seq read depth which concurred with the direction of change in the 450k data.  
However, virtually none of these coincided with a statistically significant MBD-seq 
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DMR, largely due to low read depths in the sequencing data.  While greater peaks often 
occurred just upstream or downstream of the probed CpG, coverage in those areas was 
not typically deep enough to reliably detect the 13.4% average difference among 450k 
DM sites.  Thus, although global concordance was high, the two datasets did not 
validate one another at the level of individual DMRs.  We therefore focused on the 
quantitative 450k data for further analysis. 
3.1.2.4 Summary of differentially methylated sites from the HumanMethylation450 
array 
After exclusions based on missing data, detection p-value, and predicted non-
specific binding, a total of 426,172 sites were included in analysis.  A total of 1,153 sites 
had a difference in methylation of at least 10%, with only 73 surpassing 20% difference.  
The single greatest delta (+85%) was observed for a CpG in RAP2B (chr3:152879313), 
while the only contiguous region with multiple DM probes was associated with mir-886 
(5:135416205-135416529).   
Differentially methylated sites were enriched for GO Biological Process terms 
relating to cell adhesion, nervous system development, cell communication and 
signaling, localization, ion transport and homeostasis, and a number of broad high-level 
terms such as "cell development" and "cellular process" (data not shown).  Adhesion 
term enrichments were largely driven by differential methylation of the protocadherin 
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locus.  Notably, "nervous system development" was the most significantly enriched term 
(p=2.68 x 10-9) which was neither adhesion-related nor a general global category. 
Interestingly, both hypomethylated and hypermethylated genes were enriched 
for promoter binding motifs of potentially relevant transcription factors (TFs) (Table 17), 
including the specificity protein family (SP); myeloid zinc finger gene 1 (MZF1), which is 
an effector of retinoic acid signaling; the Vitamin D receptor (VDR); and 
Leukemia/lymphoma-related factor (LRF/ZBTB7a).  More strikingly, hypermethylated 
genes showed enrichment for binding motifs of the glucocorticoid receptor (GR), AP-2α 
and AP-2γ, and CDX1/2.  To further investigate the relationship between these TFs and 
differential methylation in the twins, DM sites were annotated against publicly available 
ChIP-seq data for AP-2α and CDX2.  In total, 22% of DM sites overlapped with at least 
one TF peak, 20% with CDX2 and 3% with AP-2α.   
Table 17. Summary of term enrichments among DM sites by direction of 
methylation change. 
 
Hypomethylated Hypermethylated 
Total genes 509 genes 306 genes 
GO BP terms 25 terms 27 terms 
General GO 
BP categories 
cellular process, cell adhesion, 
organismal development, 
organismal signaling, nervous 
system development, synapse 
organization 
cellular process, localization, 
transport, organismal signaling, cell 
surface signaling, ion transport, 
response to stimulus 
 63 
 
promoter TF 
binding 
motifs 
8 motifs, 6 TFs or families 
(GATA, LRF, MZF1, SP, TFIIA, 
VDR) 
15 motifs, 11 TFs or families 
(AP-2, CDX, E2F, GR, HMGIY, LRF, 
MAF, MZF1, p53, SP, VDR) 
3' UTR 
miRNA 
binding 
motifs 
1 motif 
(miR-551b) 
2 motifs 
(miR-139a-3p, miR-560) 
 
3.1.2.5 Contrast of AN twins methylation profile with TTTS twins methylation profile 
An additional pair of monozygotic twins with twin-to-twin transfusion 
syndrome (TTTS) was also run on the array (unpublished data). The affected twin of this 
pair was anencephalic, which is not typical of TTTS (Sekiya and Hafez, 1977), but could 
have been secondary to stunted growth and nutrient deficiencies arising from TTTS.  We 
compared the differential methylation profile of these twins to that of the AN twins.  
Notably, the TTTS twins exhibited half as many DM sites (593) and approximately equal 
numbers of hypomethylated and hypermethylated loci (49% vs. 51%).  In addition, only 
32 individual DM CpGs overlapped between these twin pairs, only 12 of which were 
affected in the same directions.  The distinctly different profiles of these twin pairs 
suggest that each pair's methylation differences are not likely attributable to site-specific 
variance, but reflect the separate etiologies underlying each case. 
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3.1.2.6 Validation of selected differentially methylated sites 
Both validation methods, the EpiTyper assay and targeted resequencing, faced 
considerable difficulties in amplicon generation.  On average, about 40% of samples 
dropped out at any given site by either method, though the actual proportion of missing 
data varied widely.  Data was obtained for both members of the original MZ twin pair at 
six EpiTyper target regions (85%) and nine resequencing target regions (45%), including 
three ampicons tiling the mir-886 locus.  Roughly half of covered regions validated as 
differentially methylated between these twins (Table 18).  On average, percent 
methylation as quantitated by resequencing was 10% lower than the 450k value for the 
affected twin, and 15% lower in the unaffected.  An additional five resequencing targets 
(25%) were covered in just one of the original pair.  At three of these sites (in APC2, 
KIRREL3, and MED12), methylation values in the covered twin were comparable to 
those obtained with the 450k array (data not shown). 
Table 18.  DM loci that validated in the original MZ twin pair.  Delta values 
compare the affected to the unaffected. 
Locus DMR Original Delta Validation Delta 
LRP1B_CpG_4 2:142313484-
142313683 
MBD-seq hypo EpiTyper -27% 
APC_CpG_1 5:112116370-
112116577 
MBD-seq hypo EpiTyper -17% 
APC_CpG_2 5:112116370-
112116577 
MBD-seq hypo EpiTyper -26% 
mir-886 5:135416205- 
135416029 
450k -25% (avg) EpiTyper 
MiSeq 
-8% (avg) 
-10% (avg) 
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NR1H3 11:47279365 450k +10% MiSeq +10% 
SPTBN4 19:40995921 450k +11% MiSeq +16% 
 
Three EpiTyper target regions (43%) and five resequencing target regions (20%) 
were covered in both MZ twins and did not validate the originally observed differential 
methylation (Table 19).  Most of these loci returned as either fully methylated or fully 
unmethylated in the validation experiment, with the exception of the site in TEAD1.  
Unmethylated controls for CAMTA1, DAAM2, and TEAD1 exhibited greater 
methylation than expected, suggesting possible systematic issues with these target 
regions. 
Table 19. DM sites that did not validate in the original MZ twin pair. 
Gene DMR Original Delta Validation Values (A, U) 
CAMTA1 chr1:6871637-
6871846 
MBD-seq hyper EpiTyper 93%, 91% 
DAAM2 6:39784553-
39784752 
MBD-seq hypo EpiTyper 99%, 96% 
RAP2B chr3:152879313 450k +85% EpiTyper 2%, 4% 
GRM8 7: 126893362 450k +12% MiSeq 0%, 0% 
HES7 17: 8027961 450k -26% MiSeq 1%, 1% 
SMPD3 16: 68482518 450k -11% MiSeq 1%, 0% 
TEAD1 11: 12708608 450k -13% MiSeq 37%, 30% 
ZBTB16 11: 114068801 450k +17% MiSeq 93%, 96% 
 
3.1.2.7 Differential methylation of mir-886 
As the only set of contiguous DM probes identified from the 450k array, we 
included mir-886 in both EpiTyper and targeted resequencing validation experiments.  
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Despite the high density of associated CpGs, mir-886 was not covered by the MBD-seq 
assay, likely because both of the twins had low methylation across this region.  This 
DMR was the most robustly validated, with all associated CpGs being about 10% less 
methylated in the affected twin.  By resequencing, unaffected family members showed 
“normal” methylation of near 50% across the region (Figure 7A).  
Among DZ twin pairs, we found that most had normal methylation across the 
region (Figure 7B).  Two affecteds and three unaffecteds, all of different families showed 
very low methylation (<10%) across the region, as did two parents and an unaffected 
sibling of DZ twins (Figure 7C).  The remainder of individuals had methylation levels in 
the range of about 35% to 65%, with females generally slightly less methylated than 
males (Figure 7C). 
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Figure 7. Plots of methylation across the mir-886 locus.  A) MZ twins, their 
parents, and unaffected sibling; B) DZ twins; C) family members of DZ twins. 
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3.1.3 Discussion 
In this monozygotic twin pair discordant for anencephaly, we identified no SNVs 
potentially causative for their divergent phenotypes.  Candidate genes for both 
abnormal neural tube morphology and exencephaly exhibited significant enrichments 
relative to the rest of the exome for exonic SNVs over intronic and for synonymous 
SNVs over nonsynonymous (Table 15). This overrepresentation of synonymous variants 
may include alleles with regulatory impact that provided a permissive background for 
NTDs in these twins and sensitized to environmental risk factors. 
We did identify distinct differences in the twins' epigenetic profiles (Table 16), 
corroborated by two different profiling methods.   Notably, hypomethylated genes were 
enriched for members of the GO Biological Process term 'nervous system development' 
(GO:0007399), while hypomethylated genes were enriched for promoter binding motifs 
of the NTD candidate transcription factors CDX1/2 and AP-2α .  Using publicly available 
ChIP-seq data, we found that 22% of DM sites overlapped with footprints of the CDX2 
transcription factor.  These findings suggest that epigenetic misregulation at binding 
sites for NTD-related transcription factors may contribute to NTD etiology.  In the 
context of this twin pair, one or more such epigenetic events may have acted as a 
"second hit" in the affected twin, leading to the development of anencephaly. 
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Overall, MZ twins are much more similar in epigenetic profile than are siblings 
or DZ twins.  A study of 80 MZ twin pairs found that 65% of twins had near-identical 
genomic methylation and histone levels; the ages of twins included in this study ranged 
from 3 to 74 years, with younger twins having higher concordances (Fraga et al., 2005).  
However, even neonatal MZ twins do not have truly identical DNA methylation profiles 
(Ollikainen et al., 2010). These observed differences, given the near-identity of MZ twin 
genomic sequences, speak to the impacts of environmental and stochastic factors on 
DNA methylation.  We additionally profiled a twin pair with TTTS syndrome on the 
450k array and found distinct differences between them and the AN twins; namely, half 
as many sites were differentially methylated, and the TTTS twins had no skew towards 
hypomethylation.  Furthermore, only 12 individual CpGs were differentially methylated 
in the same direction in both twin pairs.  
However, we found that only about half of the DM sites covered by our 
validation experiments did in fact validate, whether by EpiTyper assay or by targeted 
resequencing.  Some of this discrepancy may be attributable to the PCR process as both 
validation methods were amplicon-based, however neither of our initial assays relied on 
PCR.  Additionally, we noticed in the resequencing experiment that the affected MZ 
twin generally quantitated 10% lower than it had on the 450k assay, while the unaffected 
twin quantitated on average 15% lower.  As our average 450k DM CpG had a magnitude 
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change of only 13%, this sample-specific shift may have masked some true differences in 
the validation, particularly for hypermethylated sites.  Finally, it has been calculated that 
the Infinium probes can detect between 20% to 7% differential methylation at the 95% 
confidence level, with greatest sensitivity at high or low methylation values (Bibikova et 
al., 2009).  Our choice of 10% delta as the threshold for differential methylation, 
combined with a very small sample size, likely permitted a greater number of false 
positives among sites in the middle range. 
Our single most robust finding is differential methylation across the mir-886 
locus (Figure 7).  Both of the MZ twins had low methylation across this region, but the 
affected was about 10% less methylated than the unaffected by all three assays.  Among 
DZ twins, two affecteds had similarly low methylation values, and two others were on 
the low end (<35%) of what appears to be normal (35-65%).  Conversely, six unaffecteds, 
whether twins or family members, had very low methylation, while 14 fell in the 
apparent normal range.  This suggests a tendency for NTD cases to be hypomethylated 
in this region, although hypomethylation is clearly not sufficient to cause NTDs in and 
of itself.  Additionally, we observed that mothers in these families were generally less 
methylated than fathers, an intriguing finding in the light of the female excess 
documented for anencephaly cases. 
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What significance hypomethylation at this locus may have is difficult to 
determine.  The gene itself is a subject of some controversy; initially identified as a 
microRNA, it has since been reclassified as a vault RNA based on sequence similarity.  
However, that similarity is markedly less than the conservation which exists between 
other vault RNAs, and pre-mir-886 does not colocalize with vault proteins (Lee et al., 
2011).  At the same time, it is inefficiently processed into two mature miRNAs by Dicer, 
suggesting that this ncRNA may fall into another class entirely.  Of its derivative 
miRNAs, mir-886-5p has been shown to be upregulated in brain tissue of anencephaly 
cases (Zhang et al., 2010), consistent with potential hypomethylation of the locus.  Mir-
886-5p has also been documented as regulating BAX, a pro-apoptotic factor (Li et al., 
2011b), while mir-886-3p may regulate cell proliferation and migration (Xiong et al., 
2011); the balance of these processes is critical to successful neural tube closure.  Recent 
literature suggests maternal imprinting of mir-886, which may be the first polymorphic 
imprinted locus identified in humans (Romanelli et al., 2014).  In any case, mir-886 is 
clearly an interesting gene that merits further investigation. 
One drawback of our study is the deficit of neural tissue for epigenetic analysis.  
First and foremost, neurulation happens over days 26-30 of human gestation, for which 
period very few embryos are available to be collected.  Human studies must, by 
necessity, use more-differentiated tissues obtained later in gestation.  However, 
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obtaining neural tissue from anencephaly cases even at the end of term is difficult 
because much of the brain degrades during gestation; furthermore, matching samples 
cannot be obtained from their unaffected, viable twins.  Conversely, cord blood is 
readily obtainable for both anencephalic and normal twins. 
Though the DNA used in this experiment came from PBMCs, and the tissue-
specific aspects of epigenomic profiles have been soundly attested, we believe our 
findings are nonetheless informative.  First, while much research has focused on tissue-
specific methylation, high correlations (r = 0.859)  have been documented of methylation 
state between multiple tissues (Byun et al., 2009).  Recent research has also demonstrated 
that between-individual differences in methylation are significantly correlated between 
brain tissues and blood, indicating that any given change in methylation may be 
detectable in both tissues (Davies et al., 2012).  Consistent with this correlation, several 
studies have identified loci in blood which are differentially methylated in the context of 
neurological diseases (Gregory et al., 2009; Uddin et al., 2010).   In all, this evidence 
supports that the differences we observed in these twins are likely to have been present 
in more proximal tissues as well. 
It is possible that the discordant MZ twins, although monozygotic, had some 
genetic variation we did not identify.  Although exome capture is considered to query 
the “entire exome”, in practice a number of regions (esp. first exons) are not sequenced.  
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By definition, exome sequencing also omits many intronic, UTR, and intergenic sites at 
which variants could have regulatory effects.  The MBD-seq approach we used in this 
study also has several limitations of note.  Although more sensitive than methylcytosine 
immunoprecipitation, MBD-seq does not effectively capture sequences containing few 
CpGs or sites with very low methylation (Li et al., 2010).  Such sites could be 
functionally relevant but not represented in our data.  Additionally, this method cannot 
identify individual methylated bases, nor provide percent methylation of a site, and its 
sensitivity is dependent upon read depth.  Conversely, the 450k array provides 
quantitative methylation values at single-base resolution, but is limited to only those 
sites represented on the array.  Used in combination, we found these methods to 
corroborate very well at the genomic level, and with sufficient sequence read depth, 
they may also corroborate at the site level.   
In this experiment we were not able to evaluate expression levels for genes 
associated with DMRs, another important piece of functional evidence. However, this is 
to our knowledge the first study to investigate differential methylation in NTD cases at 
the level of genes and individual CpGs, and so represents an important step forward in 
understanding the role of altered methylation in NTD etiology. 
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Chapter 4: Interactions with the environment: the case 
of fumonisin 
With a myriad of genetic and environmental factors potentially contributing to 
NTD etiology, it stands to reason that gene-environment interactions may also be 
substantial determiners of NTD risk.  Here we examine the confluence of genetic 
differences and/or epigenetic outcomes of fumonisin exposure both in a mouse model 
system and in healthy women from Guatemalan communities. 
4.1 Differential methylation in LM/Bc and SWV mouse embryos 
exposed to FB1 
Despite a partially shared genetic background, LM/Bc and SWV mouse strains 
have strikingly different susceptibilities to fumonisin-induced NTDs (Section 1.5).  The 
immediate effect of fumonisin is competitive inhibition of ceramide synthases (CERS1 
and related proteins), elevating levels of simple sphingolipids from which ceramide 
would otherwise be made, and reducing levels of more complex ceramide derivatives.  
Maternal supplementation of folate or ganglioside GM1, a ceramide-derived component 
of lipid rafts that may anchor folate receptors, has been shown to rescue FB1-induced 
NTDs in LM/Bc embryos (Gelineau-van Waes et al., 2005).  However, the mechanism by 
which FB1 exposure causes NTDs and the aspect of folate biology that rescues the 
phenotype remains unknown. 
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Both ceramide and the simple sphingolipids, sphingosine (So) and sphinganine 
(Sa), are bioactive molecules that act as secondary messengers which contribute to the 
regulation of many processes (Section 1.4.2.2).    In addition, simple sphingolipids are 
known to directly inhibit histone deacetylases (Hait et al., 2009), indicating a role for 
these molecules in epigenetic regulation.  The Gelineau-van Waes lab has previously 
shown that sphinganine-1-phosphate (Sa1P) in particular is highly upregulated in 
LM/Bc mice exposed to FB1 (Gelineau-van Waes et al., 2012), and that histone 
acetylation is greatly increased in LM/Bc embryos with FB1-induced NTDs (unpublished 
data).  This evidence suggests a role for epigenetic modifications in mediating the 
consequences of FB1 exposure, especially as folate is a required cofactor for methylation 
reactions.  To elucidate these mechanisms, we compared the epigenetic profiles of 
control and FB1-treated embryos of each strain to determine how FB1 exposure impacts 
the epigenome, and whether those epigenetic changes may contribute to NTD etiology 
in the LM/Bc strain. 
4.1.1 Methods 
4.1.1.1 Experimental animals, treatment, and sample collection 
Inbred SWV and LM/Bc mice were maintained by the Gelineau-van Waes lab at 
Creighton University as previously described (Gelineau-van Waes et al., 2012).  All 
animal procedures were performed in accordance with the Public Health Service (PHS) 
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policy on Humane Care and Use of Laboratory Animals, and approved by the Creighton 
University Institutional Animal Care and Use Committee.  Fumonisin B1 was purchased 
from PROMEC (Tygerberg, South Africa), and administered to pregnant SWV and 
LM/Bc dams on E7.5, E8.5, and E9.5 via intraperitoneal injection (20 mg/kg/day) in a 
volume of 0.1 ml per 10 gm body weight. Pregnant animals in the control groups were 
given saline vehicle at the same time points via intraperitoneal injection (0.1 ml per 10 
mg body weight).  Embryos were collected four hours after the final injection, and DNA 
was extracted using the Wizard Genomic DNA Purification Kit (Promega Corporation, 
Madison, WI), scaled down according to tissue input amounts. 
4.1.1.2 Methyl-seq library preparation and sequencing 
Regulatory regions were enriched and libraries prepared for bisulfite sequencing 
using the SureSelect Mouse Methyl-seq XT kit (Agilent Technologies, Santa Clara, CA) 
according to manufacturer’s protocol.  This kit covers 109 Mb of the mouse mm9 
genome and is designed to target CpG islands, shores, shelves, Ensembl regulatory 
features, and Open Regulatory Annotation features.  Briefly, extracted DNA was 
sheared on a Covaris S220 Focused-ultrasonicator and target regions were enriched 
through hybridization with and capture of biotinylated complementary RNA probes.  
Fully methylated adapters were ligated to enriched fragments, then samples were 
bisulfite converted using the EZ DNA Methylation-Gold kit (Zymo Research, Irvine, 
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CA) and indexed for sequencing.  Libraries were pooled two per lane and sequenced 100 
nt paired-end on an Illumina HiSeq instrument. 
4.1.1.3 Methyl-seq data analysis 
Reads were aligned to the mouse mm9 reference using Bismark (Krueger and 
Andrews, 2011) and Bowtie 2 (Langmead and Salzberg, 2012).  Bismark was also used to 
remove duplicates from the alignments.  The program Bis-SNP (Liu et al., 2012), built 
upon the GATK framework but specific for bisulfite-converted sequence analysis, was 
used for local refinement around indels and base quality score recalibration.  Bis-SNP 
was also used for methylation calling at every CpG within 400 nt of probe binding sites.  
Only sites with at least 10 reads in all four samples were included in downstream 
analyses.  Sites were annotated against RefSeq genes using ANNOVAR (Wang et al., 
2010) with a near gene threshold of 2 kb.  Methylation values, a ‘T’ at a CpG 
dinucleotide being considered un-methylated and a ‘C’ considered methylated, were 
compared between strain controls, between treated and control groups, and between the 
LM/Bc FB1-treated embryo and all three other embryos.  At least 20% difference in 
methylation at a base pair specific coordinate between ‘T’ and ‘C’ reads was required to 
consider a site differentially methylated.  Regions were considered differentially 
methylated between samples if they contained two or more CpGs within 200 nt which 
all differed by 20% or more in the same direction.   
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4.1.1.4 Validation of DM sites by high-throughput bisulfite sequencing 
Twenty DMRs localized to genes in sphingolipid metabolism, Wnt signaling, or 
Hippo signaling were selected for validation by targeted bisulfite resequencing.  Primer 
design, PCR amplification, sequencing, and analysis were all performed as previously 
described (Section 3.1.1.5).  A total of 43 samples, plus an enzymatically methylated 
mouse control (Zymo Research), were used as the validation cohort (Table 20).  A few 
whole-embryo samples were included to examine the consistency of methylation 
between head tissue and entire embryo.  Significance of methylation changes was 
evaluated for head samples only by two-way ANOVA incorporating strain, treatment, 
and strain x treatment interaction; p-values were adjusted for multiple testing using the 
Benjamini-Hochberg false discovery rate (FDR) correction. 
Table 20. Mouse sample cohort for validation by targeted resequencing. 
 LM/Bc SWV 
  control FB1 control B1 
Whole embryo 2 1 2 2 
Embryo head 8 9 9 10 
 
4.1.2 Results 
4.1.2.1 Overview of methyl-seq coverage and alignment quality 
All samples showed good alignment to reference and low duplications rates 
(Table 21).  Samples were very similar in base quality per cycle, read quality, sequence 
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content, and GC content as reported by FastQC (data not shown).  Additionally, all four 
samples had nearly identical aggregate methylation levels (38%) across profiled CpGs.  
A total of 796,195 CpGs were covered by at least 10 reads in all four samples, and 
included in downstream analyses. 
Table 21.  Alignment metrics for the mouse methyl-seq data. 
 Total Read Pairs Mapped Duplicated 
LM/Bc ctrl 16777129 70.7% 5% 
LM/Bc FB1 17914705 69.0% 13% 
SWV ctrl 25782553 70.9% 10% 
SWV FB1 31823266 71.0% 6% 
 
4.1.2.2 Differential methylation specific to LM/Bc with FB1 exposure 
We identified 31,726 differentially methylated sites specific to the LM/Bc FB1-
treated embryo.  Of these, 6,685 (21%) were within 200 nt of another DM CpG having the 
same direction of change, comprising 2,921 DMRs.  Just under one-third of DM CpGs 
(2,123 sites) were intergenic, and excluded from further analysis.  The remaining 4,562 
sites were distributed across 1,965 genes, averaging 1 DMR (2.3 DM CpGs) per gene.  
Gene Ontology (GO) Biological Process (BP) term enrichments for these genes were 
determined using g:Profiler with g:SCS multiple testing correction (Reimand et al., 
2011).  In all, 387 BP terms were significantly enriched; a best-per-parent summary is 
given in Table 22.   
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Many enriched terms were processes with relevance to NTDs, including nervous 
system development (p=9.01e-23), its child terms forebrain development (p=5.89e-03) and 
hindbrain development (p=4.92e-02), epithelial tube morphogenesis (p=2.42e-02), actin 
cytoskeleton organization (p=4.72e-03), cell proliferation (p=5.60e-05), purine nucleotide 
metabolic process (p=7.39e-04), calcium ion homeostasis (p=1.04e-03), and GTP metabolic 
process (p=2.22e-02).  Collectively, these enrichments suggest that epigenetic regulation 
of processes contributing to neural development and neural tube closure may be 
particularly impacted by FB1 exposure and/or ceramide synthase inhibition. 
Table 22.  Best-per-parent summary of GO Biological Process term enrichments for 
genes with DMRs in the LM/Bc FB1-treated embryo. 
p-value GO Biological Process Term Term ID Genes 
1.14e-32 single-organism process GO:0044699 1235 
5.55e-30 developmental process GO:0032502 563 
5.61e-28 multicellular organismal development GO:0007275 503 
4.85e-26 single-organism cellular process GO:0044763 1108 
1.79e-23 cellular component organization GO:0016043 500 
2.55e-23 localization GO:0051179 529 
5.30e-22 positive regulation of biological process GO:0048518 462 
9.87e-20 cellular metabolic process GO:0044237 835 
4.16e-19 intracellular signal transduction GO:0035556 276 
4.62e-17 cell adhesion GO:0007155 148 
1.44e-10 locomotion GO:0040011 167 
2.89e-09 enzyme linked receptor protein signaling pathway GO:0007167 103 
1.48e-04 regulation of GTPase activity GO:0043087 57 
2.69e-04 cellular response to organic substance GO:0071310 153 
2.96e-04 growth GO:0040007 108 
4.28e-03 muscle contraction GO:0006936 37 
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4.1.2.3 Overview of targeted resequencing results 
Of the 20 validation amplicons, all but one were sequenced to a depth of 35x or 
more across at least 35 samples (80%).  The Tead4 amplicon was covered to 35x in only 30 
samples (68%).  Data was obtained for a total of 134 CpGs, though due to the 
tagmentation method of library preparation, CpGs near amplicon ends were sequenced 
less deeply.  The fully-methylated control was covered at 107 CpG sites, and had greater 
than 85% methylation for all but seven.  Those seven were excluded from further 
analyses.  Generally, methylation for whole-embryo samples was similar in magnitude, 
but did appear to group separately from head tissue counterparts (data not shown).  
Though we did not have enough embryo samples to test significance, this suggests that 
methylation profiles of different tissues may be distinct even in early development. 
In total, 78 CpGs (58%) were found to have at least nominally significant 
association of methylation level with strain, treatment group, or both (Table 23).  A 
majority of strain associations (63%) passed multiple testing correction, while few did in 
other models, likely due to the small sample size and sometimes considerable within-
strain variability of methylation (see below).   Only three amplicons (Ctnnd2_B, Fat3, 
and Vgll4_A) exhibited no significant associations under any model. 
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Table 23. Summary of amplicons with significant associations (p<0.05) 
between methylation, strain, and treatment group. 
  
Strain x Treatment Strain Treatment 
Amplicon CpGs Nominal FDR Nominal FDR Nominal FDR 
Ctnnd2_A 5 1 --- --- --- 2 --- 
Ctnnd2_B 3 --- --- --- --- --- --- 
E2f2 6 2 --- --- --- --- --- 
Fat3 3 --- --- --- --- --- --- 
Frmd4a 3 --- --- --- --- 1 --- 
L3mbtl1_A 6 --- --- 1 1 --- --- 
L3mbtl1_B 10 6 --- 9 9 1 --- 
L3mbtl1_C 10 1 --- 10 7 6 --- 
Nf2 7 --- --- 1 --- --- --- 
Prickle1_A 6 --- --- 1 --- 1 --- 
Prickle1_B 5 1 --- 2 --- 1 --- 
Shmt2_A 8 --- --- 3 1 --- --- 
Shmt2_B 10 --- --- --- --- 1 --- 
Smad6 3 3 2 --- --- --- --- 
Tead4 12 --- --- 3 1 1 --- 
Vgll3 9 --- --- 3 --- --- --- 
Vgll4_A 8 --- --- --- --- --- --- 
Vgll4_B 5 4 --- --- --- --- --- 
Wwc2_A 8 2 --- 1 --- 1 --- 
Wwc2_B 7 2 --- 7 7 --- --- 
 
4.1.2.4 Strain-specific changes in methylation associated with FB1 exposure 
Of 20 amplicons in the validation set, nine (45%) were found to contain at least 
one CpG with a significant, strain-specific change in methylation with FB1 exposure.  
The most significant SNPs per amplicon are shown in Figure 8.  Generally, the 
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differences in methylation are small (<15%) both between strains and between 
treatments, consistent with other  literature on non-cancer-related methylation changes 
(Dayeh et al., 2014; Rakyan et al., 2011).   
 
Figure 8. Methylation vs. treatment group for CpGs with significantly different 
responses between strains upon FB1 exposure. Numbers on plots indicate uncorrected 
p-values and n per treatment group. 
Four additional amplicons contained sites which did not quite achieve nominal 
significance:  Frmd4a, Shmt2_A, Shmt2_B, and Tead4 (Figure 9).   Of these, two show 
apparently greater effect in one strain (Frmd4a, Tead4) or effects only in LM/Bc 
(Shmt2_A, Shmt2_B). 
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Figure 9.  Sites from amplicons with suggestive trends in methylation.  Numbers on 
plots indicate uncorrected p-values and n per treatment group. 
4.1.3 Discussion 
We identified 4,562 DMRs in the FB1-treated LM/Bc embryo compared to strain 
controls and a FB1-treated SWV embryo.  Genes with DMRs were significantly enriched 
for a number of GO BP terms relating to neural development and neural tube closure, 
including nervous system development (p=9.01e-23), actin cytoskeleton reorganization 
(p=4.72e-03), cell proliferation (p=5.60e-05), purine nucleotide metabolic process (p=7.39e-
04), and others.  These findings suggest that epigenetic regulation of genes involved in 
neural development may be particularly impacted by FB1 exposure. 
Of 20 selected DMRs from sphingolipid metabolism, Wnt signaling, and Hippo 
signaling genes, nine (45%) validated as having significant, strain-specific differences in 
methylation for at least one CpG (Table 23).  Four others approached significance 
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(Figure 9), suggesting a strain-specific trend in response at these loci. In all, 65% of sites 
selected for validation appear to have at least a trend towards strain-specific epigenetic 
changes with FB1 exposure.  This is similar to the validation rate obtained for our 
human methylation study (Section 3.1.2.6), and was likely similarly affected by the small 
sample size of our initial experiment (n=1 each strain and treatment).   
Some DMRs with strain-specific responses showed a strong change only in one 
strain (e.g. Fat3, Tead4, Wwc2), but at other sites (chiefly in L3mbtl1), LM/Bc and SWV 
mice were affected in opposite manners (Figure 8).  These data indicate that genetic 
background can influence both magnitude and direction of epigenetic change. 
In this study, we did not investigate gene expression differences.  The Gelineau-
van Waes lab has previously run Affymetrix gene expression arrays comparing LM/Bc 
FB1-treated and control embryos (data not yet published).  Of all genes with DMRs, 176 
(9%) were significantly differentially expressed, including five in the validation set 
(Ctnnd2, E2f2, Frmd4a, Shmt2, and Vgll3).  These genes are strong candidates for 
epigenetic regulation at their associated differentially methylated loci.  We do not 
currently have data on gene expression differences between LM/Bc and SWV strains, but 
these experiments are in progress. 
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4.2 Genetic variants influencing the effects of fumonisin on 
sphingolipid metabolism in Guatemalan populations 
Our mouse model of FB1-induced NTDs supports the notion that genetic 
susceptibility modulates the metabolic and developmental repercussions of in utero 
fumonisin exposure.  While there is no conclusive evidence showing that FB1 causes 
NTDs in humans, it is likely that similar genetic mechanisms influence the consequences 
of FB1 exposure in humans.  To identify potential modifiers of human FB1 exposure, we 
performed a SNP association study in participants recruited from Guatemalan 
departments with generally high (Jutiapa) or low (Escuintla, Chimaltenango) 
prevalences of FB1 in maize (Torres et al., 2014).  
4.2.1 Methods 
4.2.1.1 Sample collection and DNA extraction 
Participants were recruited by the Centro de Investigaciones en Nutrición y 
Salud, Guatemala City, Guatemala.  The research protocol and consent form were 
approved by the Comité Institucional de Ética of the Instituto de Nutrición de Centro 
América y Panamá (Project Number CIE REV003/2010), a U.S. Department of Health, 
and Human Services Office for Human Research Protections registered Independent 
Ethics Committee. The Comité Nacional de Ética of the Guatemalan Ministry of Health 
also gave its ethical approval for this project. 
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 Participants were recruited from villages in the Guatemalan departments of 
Escuintla, Chimaltenango, and Jutiapa over the course of 2011 and 2012.  Blood spots 
from finger pricks and urine spots were collected for each participant on separate 
Whatman 903 filter cards.  Sphingolipid metabolites (Sa1P and So1P) in blood spots and 
FB1 in urine were quantified via mass spectrometry by the Riley lab with the USDA – 
ARS Toxicology and Mycotoxin Research Unit (Torres et al., 2014).  DNA was directly 
whole-genome amplified from blood spot lysates using the REPLI-g Mini Kit (Qiagen, 
Hilden, Germany), following an adapted protocol available from the manufacturer’s 
website.  Amplified DNA was purified using the DNA Clean & Concentrator-5 kit 
(Zymo Research).   
4.2.1.2 GoldenGate genotyping assay 
A custom genotyping assay using the GoldenGate Universal-32 BeadChip 
(Illumina, Inc., San Diego, CA) was designed to target 125 ancestry-informative markers 
(AIMs) previously characterized for use in American populations (Kosoy et al., 2009) 
and 259 haplotype-tagging SNPs in sphingolipid metabolism, Wnt signaling, and Hippo 
signaling genes (Table 24).  AIMs were used to exclude probable first-degree relatives 
from analyses and to evaluate population stratification.  Haplotype-tagging SNPs were 
identified from HapMap release 3 MEX population genotypes using ldSelect (Carlson et 
al., 2004).  Target genes and haplotype bins are summarized in Table 24. One DNA 
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standard from the Centre d'Etude du Polymorphisme Humain and one duplicated 
sample were included on each plate as performance controls.   
The GoldenGate assay was performed according to manufacturer’s protocol by 
the Duke NTD team.   Internal spiked-in controls were used to evaluate chip 
performance, including measures of intensity and contamination.  All chips had 
generally normal values for internal controls except plate A, which exhibited low 
intensities.  This was most likely caused by a poorly performing thermocycler, which 
was not used for subsequent plates.  Genotype clusters were evaluated separately for 
plate A. 
Table 24.  Genes represented on the custom GoldenGate genotyping assay.  
Number of haplotype bins indicated in parentheses. 
CELSR1 (34) CERS1-GDF1 (1) COL3A1 (4) CTNNB1 (5) DAAM1 (12) 
DVL1 (2) DVL2 (2) DVL3 (2) EDG5 (2) GDF3 (3) 
LPP3 (17) LRP6 (6) PAX6 (5) S1PR3 (5) SGPL1 (10) 
SGPP1 (2) SGPP2 (18) SHMT1 (3) SMAD2 (5) SPHK1 (2) 
SPHK2 (1) TCF7L1 (31) TCF7L2 (38) TEAD1 (24) VANGL1 (19) 
VANGL2 (4) VGLL3 (2)    
 
4.2.1.3 Analysis of genotype data 
Genotyping performance and statistical analyses were performed by the Duke 
NTD team.  As only 384 SNPs were included on the assay, genotype clusters were 
individually evaluated for amplification success, cluster separation, and number of 
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apparent clusters.  SNPs failing these criteria were excluded.  Samples with a call rate of 
less than 90% were excluded from analyses.  Identity-by-descent (IBD) estimation was 
performed in PLINK (Purcell et al., 2007) using all SNPs to remove duplicate 
individuals.  Ancestry estimation was performed on ancestry-informative markers in 
STRUCTURE (Pritchard et al., 2000); apparent first-degree relatives and individuals with 
uncertain family membership were excluded.  These markers were also evaluated for 
population stratification using eigenstrat (Price et al., 2006).  An additional seven 
samples were removed for mismatches with earlier genotype data.  Association of SNPs 
with blood So1P or Sa1P level was evaluated using linear regression models in PLINK 
with age, location, urine fumonisin level, and population structure as covariates. 
4.2.2 Results 
4.2.2.1 Population stratification and pruning of probable close relatives 
Upon clustering review, 63 SNPs were removed for poor performance.  A total of 
321 SNPs were included in analyses, including 105 AIMs and 216 tag SNPs.  Population 
stratification analysis revealed that participants were more similar to MEX and CEU 
populations than Asian (Figure 10A) or YRI (data not shown).  Samples generally 
clustered with the MEX population (Figure 10B).  A number of samples fell just outside 
the MEX cluster, but did not clearly separate; this group may include individuals with 
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greater Mayan ancestry.  In general, however, these data support our use of the MEX 
population data for identifying haplotype tagging SNPs in this study. 
 
Figure 10.  Principal component plots showing population stratification of samples.  
A) with HapMap Asian population; B) with CEU and MEX populations only. 
Ancestry estimation identified 82 definite first-degree relatives.  For each family 
group, only the sample with highest call rate was retained.  Another 206 samples were 
excluded for relatedness where no clear family structure could be determined.  An 
additional 19 individuals were found to have duplicate samples based on IBD 
estimation.  Ultimately, a total of 440 samples were included in association analyses. 
4.2.2.2 Association of variants with phenotypic outcomes of fumonisin exposure 
Of 216 haplotype-tagging SNPs included in analysis, 22 were found to have 
nominally significant associations with sphingolipid metabolite levels (Table 25), 13 with 
So1P and 20 with Sa1P.  Eleven variants were significantly associated with both 
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sphingolipids.  Only one association, that of rs10765992 with Sa1P level, remained 
significant after Bonferroni correction.  Interestingly, most genes are components or 
targets of Wnt signaling; the only sphingolipid metabolism genes containing associated 
SNPs were PPAP2B and SGPL1. 
Table 25.  Variants significantly associated with sphingolipid metabolite 
levels.  All p-values are uncorrected. 
SNP Gene Class p (Sa1P) p (So1P) 
rs10765992 TEAD1 intronic 0.0001 0.00172 
rs10500759 TEAD1 intronic 0.0006 0.00458 
rs5767230 CELSR1 intronic 0.0070 0.00070 
rs644242 PAX6 intronic 0.0023 0.00820 
rs3026390 PAX6 intronic 0.0311 0.00288 
rs2071754 PAX6 intronic 0.0223 0.00486 
rs4757953 TEAD1 intronic 0.0061 ns 
rs1122940 CELSR1 intronic 0.0080 0.01966 
rs10885398 TCF7L2 intronic 0.0135 0.03067 
rs1866714 TEAD1 intronic 0.0136 ns 
rs11022509 TEAD1 intronic 0.0171 ns 
rs2296783 TCF7L2 intronic 0.0181 0.04817 
rs6741339 TCF7L1 intronic ns 0.02048 
rs1516454 COL3A1 upstream 0.0208 0.03420 
rs17096088 DAAM1 intronic ns 0.02751 
rs8139582 CELSR1 intronic 0.0287 ns 
rs17411627 TEAD1 intronic 0.0311 ns 
rs7513382 VANGL2 intronic 0.0335 ns 
rs1984519 CELSR1 intronic 0.0404 ns 
rs3788723 CELSR1 intronic 0.0408 0.04904 
rs2065553 PPAP2B intronic 0.0453 ns 
rs10823627 SGPL1 intronic 0.0471 ns 
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4.2.3 Discussion 
We identified 22 variants in ten genes that were significantly associated with 
sphingolipid levels in blood after fumonisin exposure (Table 25).  Eleven of these were 
significantly associated with both So1P and Sa1P levels.  Only one association survived 
multiple testing correction, that of rs10765992 in TEAD1 with Sa1P level.  The 
association of TEAD1 variants with sphingolipid levels in humans is particularly 
interesting, as this is an NTD candidate gene for which we also identified genetic 
variants between LM/Bc and SWV mice (Section 2.2.2.5) and a novel variant in our 
multiplex AN family (Section 2.1.2.5). 
Interestingly, only two genes with significant associations, SGPL1 and PPAP2B, 
were directly involved in sphingolipid metabolism.  The remainder was largely 
comprised of genes involved in Wnt signaling, suggesting the Wnt pathway may play 
an important role in regulating blood sphingolipid levels.  Sphingolipids have been 
shown to regulate Wnt and β-catenin signaling (Pederson et al., 2008; Schmelz et al., 
2001), but to our knowledge this is the first indication that Wnt genes also regulate 
sphingolipid metabolism.   
4.3 Conclusions 
The intersections of genetic variation, environmental factors, and the epigenome 
in regulating neural tube closure only underscore how complex this process is. We show 
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here that environmental factors may affect the epigenome in ways which could have 
detrimental impacts on gene expression (Section 4.1.2.2).  We have also identified 
haplotype-tagging variants which associate with phenotypic outcomes of FB1 exposure 
in humans (Sections 2.2.2.2, 4.2.2.2).  The functional impacts of these haplotypes remain 
to be determined, but taken together, these findings suggest a complex set of 
interactions may determine the ultimate outcome of fumonisin exposure. 
Curiously, we find Wnt and Hippo signaling to be the common threads 
throughout our data, even though it is ceramide synthase and sphingolipid biosynthesis 
which are directly inhibited by FB1.  This trend spans both our mouse and human 
studies, suggesting that similar mechanisms mediate the effects of FB1 in both 
organisms.  Furthermore, many of these genes are themselves NTD candidates, 
providing additional support for a role of FB1 in human NTD pathogenesis. 
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Chapter 5: Synthesis of findings, implications, and 
future directions 
5.1 NTDs as complex disease 
 As evidenced by the range of phenotypes, only briefly described here 
(Section 1.2.1), and the panoply of contributing risk factors known and possibly still 
unknown (Sections 1.3, 1.4), NTDs “are not one disease but many” (Wallingford et al., 
2013).  Our findings reflect and support this conclusion: interactions of genetic factors 
(Section 2.1), environmental or epigenetic factors (Section 3.1), and interactions between 
genetic and environmental factors (Sections 2.2, 4.1, 4.2) may all contribute to NTD 
pathogenesis.  Deciphering which mechanisms or factors are common to all NTDs, if 
any, and what is unique to the etiology of each phenotype or even each individual case 
is an ongoing challenge in NTD research. 
To date, most human NTD studies have featured small sample sizes and a 
concomitant lack of statistical power (reviewed in Au et al., 2010).  As discussed by Au 
et al., this is a natural consequence of the difficulty in ascertaining NTD cases, 
particularly for severe phenotypes.  However, even when a single research group has 
collected enough samples for a sufficiently powered case-control genetic study, they 
have largely focused on rare variants and putative mutations, even though the 
multifactorial model also supports contribution of common variants to risk (reviewed in 
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Juriloff and Harris, 2012).  Such approaches are likely to miss the complexity of 
interactions that underlie NTD etiology. 
We propose pedigree-based high-throughput sequencing experiments as a 
means for identifying interactions that contribute specifically to human NTD etiology.  
In sporadic cases, each individual is likely to possess a unique set of risk variants; with 
over 240 candidate genes already implicated in NTD etiology (Harris and Juriloff, 2007, 
2010), the potential genetic heterogeneity is considerable.  However, affecteds in a 
multiplex pedigree are most likely to have a common pathogenesis, and through the 
evaluation of genetic sharing, a ‘module’ of interacting variants – such as we observed in 
Dvl-Rho complex components of one family (Section 2.1.2.4) – can be identified and 
functionally characterized.  The variants and genes of these modules can then be queried 
in sufficiently powered case-control studies of sporadic cases to determine how 
frequently a given genetic module contributes to human NTD risk.  The Hereditary 
Basis of Neural Tube Defects study at Duke has been ongoing since 1994, and currently 
includes 5,176 individuals in 1,366 families spanning all NTD phenotypes.  Furthermore, 
our anencephaly subset includes 1,128 individuals (330 cases) from 351 families, about 
20% of which are multiplex families that contain multiple affected individuals.  Our 
cohort therefore provides an excellent basis for additional investigations of gene-gene 
interaction in human NTDs. 
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5.1.1 Functional characterization of variants in PCP genes 
In our exome sequenced multiplex anencephaly family, we identified an 
aggregation of variants that we posit collectively attenuated PCP signaling in the 
affecteds below the level necessary for neural tube closure (Section 2.1.2.4).  However, 
we did not have RNA available for this family, and could not interrogate gene transcript 
or isoform expression.  To determine what functional impact these variants have, we 
propose introducing equivalent mutations in vitro using a CRISPR-Cas9 site-directed 
mutagenesis system and use real-time PCR to evaluate gene and isoform expression 
based upon our predictions of variant splicing effects.  We are currently identifying an 
appropriate cell line to use, i.e. one with strong expression of PCP signaling genes.  
Subsequently, gene constructs for variants with validated functional effects will be 
introduced into a Xenopus model system in collaboration with the Wallingford lab at the 
University of Texas in Austin to evaluate impacts on neural tube closure, a group with 
past experience in PCP signaling and Xenopus models of NTDs (Park et al., 2006; 
Wallingford and Harland, 2002). 
5.1.2 Wnt genes as modifiers of environmental risk 
Interestingly, we found that SNPs in Wnt genes were also some of the most 
strongly associated with blood sphingolipid levels in humans exposed to fumonisin 
(Section 4.2.2.2).  These findings highlight Wnt signaling genes as potential mediators of 
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environmental risk, particularly in the context of FB1 exposure, an aspect which to our 
knowledge has not yet been explored.  The genetic variation we observed in Wnt genes 
of LM/Bc and SWV mice, such as Lrp2, Lrp6, Celsr1, and Fzd1 (Section 2.2.2.5) may 
provide a ready context for further investigation of these gene-environment interactions.  
Namely, we can assay gene expression directly in control and treated embryos, and also 
introduce single or multiple variants from the LM/Bc strain into an in vitro system to 
evaluate impacts on an individual and collective basis.  We will then be able to evaluate 
these variants for potential splicing effects and the relative expression of isoforms, as 
with the human PCP variants above. 
5.1.3 TEAD1 and Hippo signaling 
Our study of fumonisin as a potential NTD risk factor naturally began with a 
focus on sphingolipid metabolism (Gelineau-van Waes et al., 2005, 2012); however, 
components of the Hippo signaling pathway appeared repeatedly in our data, from 
analyses of mouse genetic variation (Section 2.2.2.5), human SNP associations 
(Section 4.2.2.2) and mouse epigenetic modifications (Section 4.1.2.4).  We also identified 
a heterozygous novel variant in TEAD1 among members of our multiplex anencephaly 
family (Section 2.1.2.5), and a possible site of differential methylation in discordant MZ 
twins (Section 3.1.2.6), although the differential methylation did not validate.  These data 
suggest that TEAD1 may be of particular interest in human NTD etiology. 
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TEAD family transcription factors are the major targets of Hippo signaling, 
which cross talks extensively with Shh, Wnt, BMP/TGF-β, and Notch signaling 
pathways (reviewed in Zhao et al., 2010), all processes intimately involved in neural 
development.  Tead1 is an established NTD candidate gene, identified from a Tead1/2 
double-knockout mouse strain (Sawada et al., 2008).  Mice null for Tead1 alone exhibit 
heart development defects and die around E11.5 (Chen et al., 1994), while Tead2 single-
knockouts exhibit no overt phenotype (Sawada et al., 2008), suggesting partial 
redundancy similar to that of Dvl family members (Etheridge et al., 2008).  By extension, 
TEAD1 and its interactors may comprise another important genetic module in NTD 
pathogenesis, one that to our knowledge has received little attention.  We propose 
moving forward with the functional characterization of genetic variation in LM/Bc Tead1 
and its interactors through analysis of allele-specific expression analyses and in vitro 
mutagenesis within strain-derived cell lines.  Human variants will be selected for 
functional analysis based upon findings in the model system. 
5.2 Fumonisins as NTD risk factors 
To date, little is known about fumonisin toxicity in humans, or its contribution to 
human NTD risk.  However, evidence supports FB1 as a candidate risk factor, from 
correlations between F. vertillicioides occurrence and NTD incidence to a mouse model 
for FB1-induced NTDs (Section 1.4.2.1).  Our team’s data supports that fumonisin FB1 
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exposure in humans has similar consequences for sphingolipid metabolism as we 
observe in the mouse model (Torres et al., 2014).   In future studies, we intend to 
determine whether other findings from the mouse model hold up in the human context 
as well. 
5.2.1 FB1 response profiles and genetic variation in mice and humans 
With the addition of AKR mice to our team’s model system, we now have strains 
representing minimal, moderate, and strong susceptibility to FB1-induced NTDs.  With 
metabolic and gene expression profiles of these strains, we can extrapolate 
characteristics distinctive to each phenotype group, both at baseline and upon exposure 
to fumonisin.  By expanding on our existing human data, particularly with the addition 
of gene expression profiles, we can determine how human biologic responses to 
fumonisin compare to those observed in the mice.  If human sphingolipid metabolism 
and gene expression profiles show similar trends, these data would provide a strong 
indication that FB1 affects humans much the same as it does mice, and that fumonisin 
exposure is a risk factor contributing to human NTD pathogenesis. 
5.2.2 Differential methylation relating to FB1 exposure 
The Gelineau-van Waes lab is presently developing strain-specific cell lines that 
will permit the use of in vitro techniques for functional validation.  Luciferase reporter 
constructs with partial or complete enzymatic methylation have previously been used 
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for functional analysis of DMRs (Dayeh et al., 2014; Unoki and Nakamura, 2003).  We 
propose to validate our mouse DMRs with similar constructs, using unmethylated, 
partially methylated, and fully methylated versions in control and FB1-treated cells of 
either strain.  This will allow us to investigate 1) whether a given methylation state for a 
construct elicits similar outcomes in LM/Bc- and SWV-derived cells; 2) if any functional 
effects of differential methylation also depend upon FB1; and 3) whether differential 
methylation is affected by strain specific genetic sequence (i.e. by incorporating variants 
from the other strain into constructs where appropriate).  Given our observation that 
methylation changes are associated with FB1 exposure in vivo, we may also find that FB1 
treatment in vitro leads to changes of methylation in the constructs, a possibility which 
would have to be verified or ruled out before proceeding with functional analysis. 
Ultimately, the goal will be to translate this work with differential methylation 
into the human context.  Others have previously used the HumanMethylation450k array 
on DNA extracted from dried blood spots (Joo et al., 2013) , not unlike those we have 
already collected for our genetic studies of samples collected in Guatemala.  If we can 
obtain methylation profiles from our existing samples, we can incorporate these data 
into FB1 response profiles with expression and metabolite data.  With these samples, 
collected as whole blood, we would be able to profile with the SureSelect Human 
Methyl-seq XT platform, allowing more direct comparisons.  To truly compare these to 
 101 
 
the mouse profiles, however, we would also need to obtain methylation data for mature 
female mice with chronic dietary fumonisin intake.  Such a study would also allow us to 
compare embryonic profiles with adult and determine what effects, if any, are specific to 
life stage. 
One additional avenue that was not pursued by our preliminary research is that 
in our model, some 20% of FB1-treated LM/Bc mouse embryos do not develop 
exencephaly (Gelineau-van Waes et al., 2005).  As inbred mice are known to vary 
stochastically in epigenetic profile (Li et al., 2011a), these may possess an epigenetic 
difference (i.e. an ‘epimutaton’) that protects against FB1-induced NTDs.  Regardless, 
profiles from such mice will also provide an additional filter for distinguishing 
epigenetic modifications with potential functional relevance to neural tube closure. 
5.3 Epigenetic modifications and NTD etiology 
The role of the epigenome in NTD etiology remains a chicken-and-egg quandary:  
do epigenetic changes have functional effects that contribute to NTD causation, or are 
the observed differences merely a consequence arising from other, more central 
problems (e.g. folate deficiency, diabetes)?  We have documented DNA methylation 
differences in humans and LM/Bc mice with NTDs (Sections 3.1, 4.1), and the Gelineau-
van Waes lab has also observed differences in the abundance of histone modifications 
after treatment with fumonisin, particularly H2BK12ac, H3K9ac, H4K5ac, H3K4me3, 
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and H3K27me (data not yet published); however, none of these observations resolve the 
question of causality.  A proposal for functional validation in the mouse model system 
has been described above (Section 5.2.2), but further characterization remains to be done 
in the human context. 
5.3.1 Further study of discordant monozygotic twins 
A difficulty with the use of discordant DZ twins for validation of epigenetic 
differences in MZ twins, as in this research (Section 3.1.2.6), is that these twin pairs differ 
on both epigenetic and genetic levels.  Just as genetic factors may be heterogeneous 
between unrelated cases, it is reasonable to expect that epigenetic factors may be as well.  
Accordingly, in future epigenetic research, we propose a similar pedigree-based 
profiling and comparison approach as for genetic studies.  In our ongoing ascertainment 
of NTD cases, our study has collected two additional monozygotic twin pairs discordant 
for anencephaly.  We were not able to include them in the research covered by this 
dissertation, but they will provide a basis for future investigations. 
In such an experiment, we would generate methylome profiles using a high-
throughput sequencing platform such as the Sure-Select Human Methyl-Seq XT kit 
(Agilent Technologies).  This kit covers 85 Mb of the human genome, targeting 
regulatory regions as described for the mouse version (Section 4.1.1.2), and provides 
quantitative, single-base resolution of methylation levels.  Profiles for unaffected 
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relatives as well as the unaffected twin will give a basis for filtering out naturally 
variable sites and changes less likely to contribute to NTD pathogenesis.  For validation 
of site functionality, rather than looking to other human NTD cases with their likely 
different etiologies, we would employ in vitro assays described above.  If we identify 
epigenetic modifications shared by several cases, either at individual CpG or gene level, 
then those would be candidates for screening in larger case-control cohorts as 
potentially more common elements of NTD etiology. 
5.3.2 Functional role of mir-886 
Another intriguing finding among our epigenetic studies is the hypomethylation 
of mir-886 in some NTD cases (Section 3.1.2.7).  The long form of this non-coding RNA 
has been shown to bind protein kinase R (Jeon et al., 2012), while its derivatives mir-886-
3p and mir-886-5p may have regulatory functionality similar to other miRNAs.  This 
gene is not present in mouse, Xenopus, or zebrafish, which pose both difficulties and 
opportunities for validation of its functionality in neural tube closure.  Introducing the 
full-length and processed forms of this ncRNA into zebrafish or Xenopus systems would 
provide a ready test of whether excess mir-886 promotes NTDs, without confounding by 
any endogenous version of the gene.   
However, targets of these miRNAs may not be conserved, especially in species 
that do not possess an ortholog of mir-886 to begin with.  Determination of targets will 
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be best done in human cells with tandem affinity purification (Nonne et al., 2010).  In 
this approach, cells stably expressing Flag-tagged Argonaute proteins would be 
transfected with biotinylated mir-886-3p or mir-886-5p.  Anti-Flag beads are used to 
purify Argonaute complexes from cell extracts, and streptavidin beads to pull down the 
miRNA of interest and its bound targets.  The enriched RNA can then be deep-
sequenced and analyzed to identify targets of mir-886.  This two-step procedure 
produces lower background than direct pulldown of the biotinylated miRNA, and 
allows direct identification of mRNAs physically bound by the miRNAs.  Further in vitro 
constructs can then be performed to characterize the effects of mir-886 binding upon 
specific target RNAs. 
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Appendix A: Reference Gene Sets 
A.1 Genes associated with abnormal neural tube morphology in 
mice 
This gene list was defined by the MGI database phenotype entry “abnormal 
neural tube morphology/development” (MP:0002151) and with child terms encompasses 
a total of 527 genes.  This phenotype is by definition “any structural anomaly of or 
development of the hollow epithelial tube found on the dorsal side of the vertebrate 
embryo that develops into the central nervous system (i.e. brain and spinal cord).”  
Child terms include phenotypes such as craniorachischisis and spina bifida, but do not 
include exencephaly.  Gene associations retrieved through MGI 5.15 on 10/30/13. 
A.2 Genes associated with exencephaly in mice 
This gene list was defined by the MGI database phenotype entry “exencephaly” 
(MP:0000914) and encompasses a total of 282 genes.  This phenotype is by definition 
“neurocranial defects resulting in exposure or extrusion of the brain.”  Although the 
MGI phenotype hierarchy does not list exencephaly as a child term of “abnormal neural 
tube morphology,” 172 (61%) of these genes are also associated with that phenotype.  
Gene associations retrieved through MGI 5.15 on 10/30/13. 
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A.3 Hedgehog signaling pathway 
This gene list was defined by the Gene Ontology Biological Process term 
“smoothened signaling pathway” (GO:0007224). The list used is inclusive of genes 
associated in either human or mouse, and inclusive of child terms encompasses a total of 
121 genes.  Gene associations retrieved through AmiGO 1.8 on 06/08/14. 
A.4 Wnt signaling pathway 
This gene list was defined by the Gene Ontology Biological Process term “Wnt 
signaling pathway” (GO:0016055), and includes all branches of Wnt signaling.  The list 
used is inclusive of genes associated in either human or mouse, and with child terms 
encompasses a total of 361 genes.  Gene associations retrieved through AmiGO 1.8 on 
06/08/14. 
A.4.1 Wnt-PCP signaling pathway 
This gene list was defined from literature searches, reviews on PCP signaling, 
and personal communication with Dr. John Wallingford.  The included genes are 
ANKRD6, CELSR1, CELSR2, CELSR3, DAAM1, DVL1, DVL2, DVL3, FUZ, FZ1, FZ2, FZ3, 
FZ6, HECW1, INTU, LRP6, NOTCH1, PRICKLE1, PRICKLE2, PRICKLE3, PRICKLE4, 
PTK2, RSG1, VANGL1, VANGL2, and WDPCP. 
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A.5 Sphingolipid metabolism genes 
This gene list was defined by the Gene Ontology Biological Process term 
“sphingolipid metabolic process” (GO:0006665).  The list used is inclusive of genes 
associated in either human or mouse, and with child terms encompasses a total of 135 
genes.  GDF1 is not included.  Gene associations retrieved through AmiGO 1.8 on 
06/08/14. 
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Appendix B: Primer Sequences 
B.1 Human PAX6 and TEAD1 validation primers 
These primers were used to validate novel variants as described in 
Section 2.1.1.6.  Products were amplified using a touchdown protocol of 64-58 C. 
Table 26.  Primer sequences for validation of novel variants in PAX6 and TEAD1. 
Region Forward Primer Reverse Primer 
PAX6 intron 6 AAGTGCTGGACAATCAAAACG GGTGGGAGGAGGTAAAGAGG 
TEAD1 intron 
10 
GAACCATTTCCCCTCCAGA TAAAAAGCCCCAGCATCATC 
 
B.2 Mouse Cers1-Gdf1 exon 8 validation primers 
These primers were used to validate rs32650885 and rs47220823 in representative 
LM/Bc and SWV mice as described in Section 2.2.1.2.  Products were amplified using a 
touchdown protocol of 64-58 C.   
Table 27. Primer sequences for validation of LM/Bc and SWV variants in Cers1-Gdf1 
exon 8. 
Function Forward Primer Reverse Primer 
PCR amplification CTCCCTGCTGCTGGTGAC TCTCGTGATTGAGGGGCTAC 
Nested sequencing 
primer 
 ACCTGAGAGATGCGAGAAGC 
  
B.3 Human methyl validation primers 
B.3.1 Primer sequences for the EpiTyper assay 
These primers were used to amplify target DMRs from the discordant MZ twin pair for validation by EpiTyper assay.  
Products were amplified following the kit manufacturer’s protocol.  
Table 28.  Primers used in the EpiTyper assay for validation of human DMRs.  EpiTyper-specific tags given in lowercase. 
Gene Forward Reverse 
APC aggaagagagTGTGAATATTGATTATGTTGTTTAGT
AGT 
cagtaatacgactcactatagggagaaggctTCACATCAAAAATC
CAAATTAAATC 
RAP2B aggaagagagTGTAGTTTTGTATAAAGAAAATAGG
AGG 
cagtaatacgactcactatagggagaaggctATACAAAAACTTCC
TACTTCCAAACC 
DAAM2 aggaagagagGTGGAGTTAAGGATATTTAGGTTTG cagtaatacgactcactatagggagaaggctTTTAATCCTAACCTC
CCAAAAAAAC 
CAMTA aggaagagagTTGGGTTTTATTTAATATTGTGATTTG cagtaatacgactcactatagggagaaggctACTATCTAAAAACC
TCCCTTAATCC 
GLI3 aggaagagagGGAGATTAATAGGATATGTGGGTTT
T 
cagtaatacgactcactatagggagaaggctAACTCTTAAAAATT
CAAAAACAAACTCAA 
miR886 aggaagagagAGTTTGGTTGTTGGATTTAGGTAGA cagtaatacgactcactatagggagaaggctACCCCAACACAAA
AATAAACAAATA 
LRP1B aggaagagagTGAGGTATTTGGTGAGTGTAGAGTA
TT 
cagtaatacgactcactatagggagaaggctCCCTAACAATAAAC
ACATAAACCTATTT 
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B.3.2 Primer sequences for targeted bisulfite resequencing 
These primers were used to amplify target DMRs from the discordant MZ twin pair for validation by high-
throughput sequencing (Section 3.1.1.5).  All pairs were optimized on a standard PCR program (not touchdown), with 
annealing temperatures and Mg2+ concentrations specific to each amplicon. 
Table 29.  Primers used in targeted bisulfite resequencing for validation of human DMRs. 
Region Forward Reverse Mg2+ Anneal 
APC2 AGTTTAGTTGTATGTAAGTGGGTGT ACTAACCTACCCATCCCTTC 3.5 mM 58 C 
APC2 GTTGATGGATAGTGATTGTTATTG TACACCAAACAAATAACTTTACATT 3.5 mM 54 C 
BCOR ATAGTTGGGTTTTATGTAAGGTTTA CCACCACCACCACTACTACTAA 1.5 mM 55 C 
GRM8 TTTTGAAATAGTAAGTAATGGAGGA TCACACACTAACAATCTACACAAAC 3.5 mM 56 C 
GRM8 GATTGTGTTTGGGATTGTTAAT CACAACCATATTCCTTCTTCTAC 3.5 mM 54 C 
HES7 TAGTTGAGATAGGGAGTAATTTGAG TAACTACTTAATATCACATAATCTTTTCC 3.5 mM 51 C 
KIRREL3 AATAAGGTAGGAAAGATTTGTGAG ACTAAAACTAACTACCAACCCTACA 3.5 mM 58 C 
MED12 TTATTTTGTGTGGTTTTTATTATGT ACAAATCATCCTAAATAACTACCAA 3.5 mM 53 C 
MSX2 TTGTTTGAAGTTATAGAATGGGTAG ACACAATAAACAATCACAAACTATC 3.5 mM 51 C 
NCOR2 TGTGAGAAAGTTTAGGTAGGATG CTCCCTCTCTATCAAATAAATAACA 3.5 mM 55 C 
NR1H3 TAAGAGTTGTTAAGAGTGTTGGGTA TCCTTCCTACCTAATAACCACA 1.5 mM 55 C 
RARA TTTGATGTTGAGTAGTATTAGGG ACACAACACAAACAAACTCAC 3.5 mM 57 C 
SMPD3 ATTTAGTATTTGGAGTGGTGAATAG TTACCTACCCACAACATAAACC 3.5 mM 56 C 
SPTBN4 TTTTTAGAAGGATTGAGTTTTGT ACATTCTCCAAATACACACACTAC 2.5 mM 52 C 
TEAD1 TGGTGTTTAGATTTTGTTGTTG AAACAATACAACATCATCTTCC 3.5 mM 53 C 
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ZBTB16 TTAGTGGTTGGTTTTAGAGGAG CCTAAACTTTCTCATATTAAATTCC 3.5 mM 56 C 
miR886 GTGGGTTTTGAATTTTAGTATAGAG AAAACACATTAACAAAACACCTAA 3.5 mM 54 C 
miR886 AATTATAGAAGAGTGATGATGTGG AAATACTCCTCAACAACCTAACTAC 3.5 mM 55 C 
miR886 TTTTATTTGGTAGTATAGGTTGGTT CATACCAAACTTTCTATCTATCCAT 3.5 mM 54 C 
miR886 TTATTTGTTGTGGTTTAATAGGTAA AACCACTAATCTTACAAAACATACA 3.5 mM 54 C 
 
B.4 Mouse methyl validation primers 
These primers were used to amplify target DMRs identified in an FB1-treated LM/Bc mouse embryo for validation by 
high-throughput sequencing (Section 4.1.1.4).  All pairs were optimized on a standard PCR program (not touchdown), with 
annealing temperatures and Mg2+ concentrations specific to each amplicon. 
Amplicon Forward Reverse Mg2+ Anneal 
CTNND2_A TTAGAGTAAAGTTTTTAGGAAGGAG ATACAACCTTACAAAATTAAAACAC 2.5 mM 54 C 
CTNND2_B ATTTAGTGGAAGATTGTTTGATATG CCTTCTATATTCCAACAACTAATTC 2.5 mM 51 C 
E2F2 TAGGTTTTTGGAAGTAATGAGTAGA ATCTATTCCCCAAACACAATC 3.5 mM 55 C 
FAT3 TTAAGTTTAGGAAGAAGATGAAGG CCACAAACTATACTTCTAACTTTCC 3.5 mM 55 C 
FRMD4A TTAAGAATAAATTGTTGTGTGTAGG TACACAAACCTCAACCCTCTC 3.5 mM 56 C 
L3MBTL1_A GATATTAAAAAGTGGTGGGTTT ATACCTTCTACACTTCCATTAAACA 2.5 mM 50 C 
L3MBTL1_B GTTATTGAATATGATAGGAGTGGAG AAAAACCACTAAACCTCAATCTT 3.5 mM 55 C 
L3MBTL1_C GAGTTTGAGTGTGTTGTTTATGG TAATCCACATTCTCCTAAAACTAAC 3.5 mM 56 C 
NF2 TGTATGAGGTATTGTTGTAGTTAGTG ATTAAACAAATTTCAATTCCTCAAC 2.5 mM 55 C 
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PRICKLE1_A ATTTTGAAAAAGAATAAAGAAGTGG ATATAATCCACCTCAACAAATAACA 3.5 mM 54 C 
PRICKLE1_B GTTATTTTTATGGAGTTGTTTTGA CAACTAACCTTTTTCTAACTAAACC 3.5 mM 55 C 
SHMT2_A TTTTTGATTGATTGTTAGGTGTT ACTAATAAATAACTTCAAAAATCCT 2.5 mM 50 C 
SHMT2_B TTGTTAGAGTTTATAGGTTGTAGGG TTCCCTCTTCTCTATACTATCCTCT 3.5 mM 53 C 
SMAD6 TAGTAGGGAAAGAAGTTATGGTTT ATAAATCCTCCTACCTCAAAATACA 3.5 mM 56 C 
TEAD4 GGTGAAATAAATTTGGGTTAGTAG ATACATCCAAATAAAAACTACATCC 3.5 mM 52 C 
VGLL3 TGGTTTATTTTTAATGGAGGAA ATTAAAACAAAATTTACAACCCTCT 3.5 mM 53 C 
VGLL4_A GTGGTGATTGTTGAGTGTAGAG TTAACAATAACTACATACCCAAACC 2.5 mM 58 C 
VGLL4_B ATGTAATGATTTTGTTAGATTTTGT CTCTTTACTTTTATAATAACCACTCC 2.5 mM 55 C 
WWC2_A ATGTTGGATATTGAGTTGTAGTTGT CAAAACATACTACCTTCCTCTTTAC 3.5 mM 56 C 
WWC2_B GGGATAAAGAGGATTTATAGTATGTT ACTTCACTTTAACACTTCACTCAAC 3.5 mM 52 C 
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